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Abstract
The Coding Region-Determinant Binding-Protein (CRDBP) belongs to a family 
of RNA-binding proteins involved in embryogenesis and oncogenesis. Accumulative 
evidence suggests that the physical interaction with target mRNAs is a critical 
determinant for CRDBP function. The goal of this study is to better understand the 
CRDBP-RNA interaction. The role of the glycine-X-X-glycine motif in each of the KH 
domains of CRDBP for RNA binding in vitro, in cells and in vivo was investigated. 
Smaller RNA fragments of c-myc, MITF, MAPK4 and p-TrCPl bound by CRDBP were 
determined and used for in silico analysis. Overall, the results showed that the G-X-X-G 
motif in the KH domains of CRDBP are critical for RNA binding, and that the KH 
domains play differential roles in binding different RNA molecules. The mapped smaller 
RNA regions aid in discovering inhibitory molecules and in silico analysis leading to 
improved approach for understanding the CRDBP RNA interaction.
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1Chapter 1- Introduction
1.1 Gene Expression and Post Transcriptional Regulation of Gene Expression
One of the critical molecular processes in life is gene expression, the transfer of 
genetic information within the cell: from the nucleus, stored as deoxyribonucleic acid 
(DNA) to ribonucleic acid (RNA) and then to protein. At each of these steps, from DNA 
to RNA (transcription), RNA to protein (translation), at the protein level, and in transition 
between these steps is where regulation can occur. Six major points of control are, (i) 
control of how often a gene is transcribed (transcriptional control), (ii) control of the 
splicing and processing of pre-RNA transcripts (RNA processing control), (iii) selection 
of which mature mRNA are exported from the nucleus and where they are localized in 
the cytosol (RNA export and localization control), (iv) selection of which mRNA are 
translated in the cytosol (translation control), (v) selectively destabilizing specific mRNA 
in the cytosol (mRNA degradation control), and (vi) selectively activating, deactivating, 
degrading, or localizing specific protein after translation (protein activity control) (7).
For most genes, the major regulation point is at transcription, as this ensures 
exorbitant gene expression is prevented. However, once a gene is expressed, tight 
regulation of the mRNA is required to prevent cellular deregulation and disease. Post- 
transcriptional regulation, specifically at the level of translation and mRNA degradation, 
is how a loss of regulation can lead to pathogenesis. During stages of embryonic 
development, up until and including apoptosis, translational regulation influences cellular 
processes.
21.2 mRNA Stability and mRNA Degradation Pathways
1.2.1 mRNA Processing, Half-Life, and Stability
How is mRNA half-life regulated and how does the process of mRNA 
degradation influence gene expression? The current knowledge of mRNA stability and its 
relationship to the control of gene expression aims to answer these questions.
The half-life of eukaryotic mRNA ranges from 10-15 minutes for some genes 
(e.g. c-fos proto-oncogene) to several hours (>10hrs) (e.g. house-keeping genes such as 0- 
actin) (8). The longevity of mature mRNA in the cytoplasm is influenced by cis-elements 
(sequences at 5'-UTR, 3'-UTR and coding region) and trans-acting factors (ribonucleases, 
RNA-binding proteins, miRNAs, non-coding RNAs).
The 5' cap of mRNA acts as a regulation point, required for export through the 
nuclear pore after recognition by the cap binding complex. Capping of the 5' end of 
mRNA with a guanosine triphosphate (GTP) in a 5' to 5' phosphate linkage, and 
methylation at the 7-nitrogen (m7G) protects the 5' end from exonuclease degradation (9). 
Messenger mRNA stability is enhanced by the 5' cap in conjunction with eIF-4E/eIF4G 
and the 3'-polyadenylated tail forming a loop structure, which promotes translation by 
recruiting the 40S ribosomal subunit (9).
The 3'-end of the mRNA is polyadenylated before export from the nucleus. The 
polyadenylated tail is preceded by an AAUAAA signal sequence and the polyadenylation 
ranges in length from 80 to 250 nucleotides, serving to protect mRNA from 3'-end 
degradation. The poly(A) tail also aids in the exportation of the transcript from the 
nucleus, as well as in promoting translation (10).
31.2.2 mRNA Degradation Pathways
An important part of regulating mRNA degradation is breakdown of the transcript 
via exonucleases and endonucleases through the standard or specialized mRNA decay 
pathways. Having the ability to degrade transcripts, allows the cell to abolish any further 
protein production, controlling translation levels, protein levels and how the cell develops 
and responds to environmental factors.
Exonucleolytic degradation is the destruction of the RNA transcript from its 5' or 
3'-end. These two events can occur independently of each other to halt translation, or 
deadenylation at the 3’ end can occur followed by decapping at the 5' end before 
transcripts are degraded exonucleolytically (11).
The 5'-to-3' degradation pathway begins with excision of the m7G cap, which 
protects the 5' end of the RNA (11,12). This decapping action is enzymatically 
facilitated by Dcplp and Dcp2p, which exposes the 5' end of the transcript to Xm lp, a 
major 5'-to-3' exonuclease (12). For 3'-to-5' exonuclease activity, the poly(A) tail is first 
deadenylated in mammalian cells by PARN to allow the exosome complex to degrade the 
transcript in a 3'-to-5' fashion (11).
Endonuclease cleavage within the body of RNA exposes both a 5'-end and 3'-end 
site of mRNA that can be easily degraded by X m lp and the exosome as mentioned 
above. However, this mRNA degradation pathway is still not fully defined. This is 
mainly due to the difficulty in detecting endonucleolytic mRNA decay products and 
hence the responsible endoribonucleases (11).
RNA interference (RNAi) is an example of a well-characterized two-step 
endonucleolytic pathway. First, dsRNA is formed by micro RNA (miRNA) or small
4interfering RNA (siRNA) with the mRNA. The mRNA is then cleaved by the enzyme 
Dicer, into 20-25 base pair fragments known as siRNA. Second, these siRNA are 
unraveled into single stranded RNA (ssRNA) and bound by the RNA-induced slicing 
complex (RISC). RISC then uses this ssRNA, as a guide strand to bind other mRNA and 
cleave them with its catalytic Argonaute protein unit (13). Similarly, miRNA, which 
binds to mRNA, result in the mRNA being endonucleolytic cleaved by RISC.
Specialized mRNA degradation pathways act as a mode for controlling the quality 
of mRNA being translated. For example, in nonsense-mediated decay, mRNA containing 
a premature stop codon are decapped and destroyed before truncated proteins with 
deleterious properties are made (14). In the case of non-stop mRNA decay, a ribosome 
becomes stalled due to lack of a stop codon, Ski7p adapter protein binds to the stalled 
ribosome and recruits the exosome to mediate the mRNA decay (15). In some cases, the 
ribosome stalls mid-translation, then no-go mRNA decay occurs involving Dom34p and 
Hbslp (16). In AU-rich element (ARE) mediated decay, adenine (A) and uracil (U) rich 
regions, or elements containing a 5'-AUUUA-3' sequence, promote the binding of ARE- 
binding proteins, resulting in increased deadenylation and endonuclease activity of the 
transcript (17). Other mRNA degradation pathways exist, aside from the mRNA 
degradation pathways mentioned above.
Amongst all of these pathways, one with marked relevance is the regulation of 
specific mRNA by microRNAs (miRNA). How RNA-binding proteins that recognize 
sequences in the untranslated regions (UTR) of the RNA and interrupt the miRNA 
mediated mRNA decay is of importance.
51.2.3 cis-Acting Elements
Sequences of RNA, called cis-elements, provide mRNA an additional mode of 
post-transcriptional or translational control by interacting with specific trans-acting 
factors.
Early examples of cis-acting elements, which allow for alternate gene expression 
and regulation by initiation of translation, was originally identified in virus RNA 
genomes, called internal ribosome entry segments or sites (IRESs) (18). These IRESs 
initiated translations via recruitment of the ribosome in the coding region, far downstream 
of the initial start codon and without the presence of a 5'-cap structure (cap-independent 
translation) (19-21). Although there is no strong evidence for either of the primary or 
secondary structures of IRES regions being responsible for this recruitment, most IRESs 
are GC-rich and therefore considered to have a complex secondary structure, suggesting 
secondary structure could play a key role in the function of IRESs (18).
Adenylate/uridylate-rich elements (AU-rich elements or AREs) are a cis- 
regulatory element located in the 3'-UTR of several proto-oncogenic mRNA (22). These 
AREs are destabilizing determinant regions that down-regulate mRNA half-life (22, 23).
Iron response elements (IREs) are located at the 5-UTR and 3-UTR of Ferritin 
mRNA and Transferrin mRNA respectively (24). These IREs control the translation and 
degradation of Ferritin mRNA and Transferrin mRNA respectively (7).
The coding region instability determinant (CRD) is another cis-acting element 
found in c-myc, c-fos, interleukin-2 and other mRNAs (25). The CRD is defined as a 
pause site, due to a string of rare codons, which forces the ribosome to wait until a scarce
6aminoacyl-tRNA arrives thus pausing the translation (25). This pause correlates with 
mRNA instability, allowing endoribonucleases to target the mRNA at the CRD site (25). 
The CRD acting as a destabilizing element can be protected from CRD-binding protein 
(CRDBP) by binding to the CRD site (25, 26). Once the CRD is bound by CRDBP, the 
mRNA half-life increases due to the protection from endonucleolytic degradation at that 
site (26).
From the above examples, it is clear that cis-acting elements play an important 
role in the control of mRNA degradation and translation. It also pointed out how the 
interaction between mRNA and protein can dictate the fate of an mRNA
1.2.4 trans-Acting Factors
These proteins, which interact with cis-acting elements, are called trans-acting 
factors (TAFs), or internal initiation trans-acting factors (ITAFs). ITAFs are thought to 
be responsible for initiation of translation when cap-dependent initiation is decreased, but 
also regulate mRNA decay through ribonucleases (RNases), microRNAs (miRNAs) and 
RNA-binding proteins (RBPs) (27).
As discussed in section 1.2.2, ribonucleases are protein enzymes important in cell 
metabolism. They control mRNA levels by catalyzing the degradation o f mRNA into its 
component pieces. Two major groups are the endo and exo RNases. Exo RNases 
degrade RNA from either the 5'-end or 3'-end in a 5'-to-3' or 3'-to-5' direction 
respectively. These proteins function as TAFs by recognizing specific regions of ssRNA, 
dsRNA and RNA-DNA hybrids.
A class of short (~22nt) noncoding RNA, known as microRNAs (miRNAs) play 
an important role in controlling post-transcriptional gene expression by mRNA
7degradation (28). In processing from pre-miRNA to mature miRNA, the mature miRNA 
associate with proteins, forming the RNA Induced Silencing Complex (RISC). This 
RISC complex that acts as a TAF to locate and bind to specific mRNA, regulating their 
half-life, as part of normal cell metabolism and gene regulation at the mRNA transcript 
level.
There are thousands of genes being regulated by miRNA at the transcriptional 
level, examples of specific interest are miR-183 with coding region of P-TrCPl and miR- 
340 with 3-UTR of MITF (29, 30). Both of these transcripts, which are down regulated 
by miRNA at targeted sites, are also protected by CRDBP, in the same regions preventing 
miRNA degradation of those transcripts (29, 30).
In conclusion, trans-acting factors can regulate gene expression at the post- 
transcriptional level, via interaction with mRNA.
1.3 RNA-Binding Proteins
1.3.1 Well-characterized mammalian mRNA-binding proteins
It is clear from the above discussion that RNA-binding proteins (RBPs) play a 
critical role in the post-transcriptional regulation of mRNA. In turn, the mRNAs bound 
by RBPs are known to play significant roles in many cellular processes, which include 
cell signaling, division, growth, development and cancer biology. Despite this, there is 
still a vast lack of studies on mRNA-binding proteins (31, 32).
Three well-characterized mRNA-binding proteins are HuR, CUG-BP, and FMR1. 
HuR, (also known as ELAVL1) is known to bind to several mRNAs including cytokines, 
interleukins and the 3'-UTR of CAT1 mRNA, which codes for a cationic amino acid
8transporter in the liver (33, 34). In human hepatocarinoma cell under cellular stress, HuR 
loses the ability to bind to the 3'-UTR of CAT1 mRNA and results in the release of CAT1 
mRNA from P-bodies and recruitment to polysomes (31, 32, 35). This 3'-UTR region of 
CAT1 is the site for miRNA-122 binding, which end in translational repression and 
accumulation in P-bodies (32, 35).
CUG-BP, also known as Elav like family of RNA binding protein-1 (CELF-1) 
regulates several steps of RNA processing, and found in early embryonic development, as 
well as heart and skeletal muscle function (36). CELF-1 functions as a mRNA stability 
factor, and plays a role in myotonic dystrophy (DM), a form of muscle dystrophy 
affecting the skeletal and heart muscle (36). The onset of DM is seen as related to 
overexpression of CLEF1 due to CLEFl’s importance in striated muscle function and 
RNAi knockdown of C. elegans homolog (ETR-1) results in defects in muscle attachment 
(36).
Fragile X syndrome is an inheritable disease that presents as constrictions on two 
arms of the X chromosome resulting in learning disability (37). This constriction in the 
arms of the X chromosome causes a loss of FMR-1 RBP, altering brain development, and 
in severe cases the protein is expressed, but caries a point mutation in the second K 
homology domain (I304N) (38).
Additional characterized family of RBPs is the VICKZ family of RBPs that 
includes coding region determinant binding protein (CRDBP). CRDBP is implicated in 
protecting mRNA during embryonic development and is also highly associated with 
cancer. CRDBP is the focus of this thesis and is discussed in greater detail in the 
following sections.
91.3.2 VICKZ, CEDBP Family of RNA-Binding Protein Orthologs and RNA Partners
There are a number of different RBPs with most RBPs consist of a few RBDs. 
One highly conserved family of RBPs responsible for recognizing specific cis-acting 
elements in variety of different RNAs, the VICKZ family (Figure 1) (1, 39,40).
The VICKZ family of regulatory RBPs consist of the proteins Vgl RBP/Vera, 
JMP-1,2,3, CRDBP, KOC, and ZBP-1, all homologs consisting of two RRMs at the N- 
terminus of the protein and four KH domains at the C-terminus (40). Originating from a 
wide range of different organisms, all these proteins interact with mRNA and result in 
aiding of localization, stabilization and translocation of their target mRNA which are 
implicated in cell polarity, cell migration, cell proliferation and cancer (39). These post- 
transcriptional changes experienced by the mRNA in the presence of VICKZ proteins is 
seen as a source for the invasive, mobile and uncontrolled cell proliferation 
characteristics associated with cancer.
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Figure 1. The VICKZ Phylogenetic tree indicating each orthologs accession number 
and the number of amino acid substitutions. Adaptation from Bell et al., 2013 (1).
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Vgl RBP and ZBP-1 were recognized for RNA trafficking mechanism with 
specific RNA targets in Xenopus laevis (frog) oocytes and Gallus gallus (chick) embryos, 
respectively. Based on Vgl RBP’s high affinity binding to the 3'-UTR vegetal 
localization element (VLE) of Vgl RNA, and ability to localize the RNA to the vegetal 
cortex in X. laevis oocytes, Vgl RBP is considered to be part of a larger complex of 
several RNA binding and motor proteins. The ZBP-1 present in G. gallus embryos is 
responsible for the leading edge of migrating neurons and fibroblasts (41,42).
Nielsen and colleagues researched the human insulin-like growth factor II 
mRNA-binding proteins IMP-1, IMP-2 and IMP-3 on the basis of their ability to regulate 
translation of the IGF-II mRNA. It has also been shown in HeLa cells that IMP-1 and 
IMP-3 help orchestrate the formation of invadopodia and regulate cellular adhesion 
through binding with CD44 mRNA (43). IMP-1 binds to the IGF-II mRNA at the 5' 
UTR, and in transgenic mice an increase in IGF-II protein can be measured after over­
expression of IMP-1, leading to the induction of mammary tumors (44). Other oncogenes 
regulated by IMP-1 are H I9 mRNA at the 3'-UTR, Tau mRNA at the 3'-UTR and c-myc 
mRNA at the coding region determinant (45-47).
From the study on pancreatic carcinomas and hepatocellular carcinomas, Mueller- 
Pillasch found the KH-domain-containing protein is over-expressed in cancer (KOC)
(48). KOC is a synonym for IMP-3.
1.3.3 The Molecular Basis of RNA Binding Proteins: Well-Characterized 
RNA-Binding Domains
When a protein interacts with nucleic acid, many non-covalent interactions are 
formed, with four main definitions of interaction (49). The first manner is the protein
11
side chain and the RNA nucleobases and is the major form of sequence specific 
interactions. Specificity arises due to the complexity and complementary of hydrogen 
bonding, van der Waals forces, hydrophobic attractions and global electrostatic forces 
presented by both protein and RNA (49).
The next possible mode of interaction (between protein and nucleic acid) can 
occur at the protein side chain with the phosphate backbone of nucleic acid. This 
commonly takes place as positively charged amino acids such as lysine and arginine 
attracted to the negatively charged phosphate backbone (49). Hydrogen bonding can also 
take place between the backbone of nucleic acid and side chain of protein, or amine 
groups of the protein backbone (49).
The last two ways in which protein can interact with nucleic acid is through the 
amine groups in the protein backbone with either the nucleic acids nucleobases or 
phosphate backbone (49). Often backbone contacts are considered a means of non­
specific binding, however a protein can recognize and interrupt specific tertiary structure 
of nucleic acid, particular single stranded RNA (ssRNA), of which is dependent on 
particular base sequences (49). This then allows for such contacts to be used for 
sequence specific interactions. This basic understanding of how protein and nucleic acid 
could interact provides insight for how different protein domains recognize and interrupt 
RNA, and how ensembles of RNA-Binding domains (RBDs) in combination give rise to 
specificity and diversity of function.
RNA localization, stabilization, processing, rate of translational control, and 
nuclear export all naturally take place in the presence of proteins, by formation of 
protein-RNA complexes known as ribonucleoproteins (RNPs) (50). This diversity of
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RNA-binding proteins (RBPs) outnumbers the handful of RNA-binding domains (RBDs) 
they are made of and therefore the diversity of RBPs stems rather from the presence of 
multiple domains and their arrangement, as opposed to a wide variety of RBDs (50). The 
repetition of multiple similar domains is thought to provide the protein with increased 
affinity and specificity compared to individual domains, where individual domains tend 
to bind with a weak affinity for shorter stretches of RNA. By having several domains 
together allow increased lengths of RNA to be recognized and for the recognition of 
certain stretches of RNA to be separated by some lengths of nucleotides, or sequences 
that belong to two different RNAs. These individual domains can then evolve 
independently to better suit the proteins function. The six RBDs that will be discussed, 
are RNA Recognition Motifs (RRMs), heterogeneous nuclear ribonucleoprotein K- 
Homology domains (hnRNP KH domains), Double-stranded RNA Binding Domains 
(dsRBDs), SI Domain, PAZ/PIWI Domains, and Zinc-Fingers.
RRMs or Ribonucleoprotein (RNP) domain are the best-characterized RNA- 
binding motif that were first found in yeast polyadenylated-binding protein and then in 
250 additional proteins (50). Consisting of 80 to 90 amino acids in length, to form a 4- 
stranded anti-parallel p-sheet packed against two a-helices giving a split ap topology of 
P -a -P -P -a -P  (49, 50). From crystalized RRM-RNA complexes, most show the p-sheet 
surface acts as the point of RNA recognition, and binding by three conserved residues of 
Arg or Lys, which forms a salt bridge with a phosphodiester backbone and two aromatic 
residues, making stacking interactions with nucleobases (49, 50). This is located within 
the domain on the central p-strands of the four-strand p-sheet, as two conserved motifs, 
RNP1 and RNP2 (49, 50). These RNP motifs are responsible for RNA binding
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specificity of two nucleotides. An additional two nucleotides are recognized on either 
side of this central region, and by utilizing the other secondary structure and exposed 
loops not found in the canonical structure of the RRMs, a total of four to eight 
nucleotides can be recognized. A classic example is the U la spliceosomal protein 
containing two such RRM domains that binds to the hairpin o f U1 snRNA (51). This 
structure is solved, and shows that the P-sheets form a binding platform allowing 
nonspecific interactions between the U1 snRNA hairpin and a highly negatively charged 
loop of residues, which join the two p-strands in the sheet (51). Here the RNA 
conformation is stabilized in order for the RRM to have specific interactions at the RNP1 
and 2 motifs. Due to the small number of nucleotides recognized at one time (by a single 
RRM domain), multiple RRM domains are needed in order to obtain specificity and 
unique binding sequences. Aside from its original finding of being a RNA Recognition 
Motif, RRMs do not all interact with RNA. In fact, some interact with protein (52).
K-homology (KH) domains, more formally hnRNP-KH domains, were first 
identified in the heterogeneous nuclear RNA-binding protein, hnRNP K, which contains 
3 copies of this domain. The VICKZ family of proteins and FMR1 protein are other 
examples of KH domain containing proteins (53). The FMR1 has been established as a 
clear clinical target, where a mutation near a key signature sequence causes fragile-X 
mental retardation syndrome (53, 54). The KH domain is noted to span the eukaryotes, 
eubacteria and archaea domains of life. This protein domain is close to 70 amino acids in 
length and is composed of 3 p-sheets packed against 3 a-helices, and two alternate 
topologies exists giving rise to two types of KH domains (49, 50). Type 1 is P-a-a-p-P-a 
and type II is a-p-p-a-a-P (Figure 2) (2,49, 50). In both types there is a signature
sequence near its center of (I/L/V)IGXXGXX(I/LV) and four nucleotides are recognized 
in a cleft, due to a G-X-X-G loop motif (50). This G-X-X-G motif flanks the helices of 
the p-strand from a-2 (Type I) or a-3 (Type II) and a variable loop between p-2 and P-3 
(Type I) or between a-2 and P-2 (Type II) (2,49). Unlike the RRM, the binding platform 
has no aromatic amino acids, and recognition of RNA is through hydrogen bonding, 
electrostatic interactions and shape complementarity (50).
Type I KH domain
KH minimal motif
f ....................11............ — "L --------------------------- j
G- X X C  motif
Type II KH domain
KH minimal motif
 . i ............  :.......j
G-X X G m otif
Figure 2. Illustration of the Type I and Type II KH Domains. Indicated in black is 
the minimal KH motif requirement with p-strands labeled as arrows and a-helices as 
cylinders. Adaptation from Fig. 1 of Valverde el al 2008 (2).
Double-stranded RBDs can be as short as 65 residues, but tend to range from 70 
to 90 and are found in several proteins which bind dsRNA in bacteria and eukaryotes (49, 
50). Like the KH domain, the dsRBD is centered on a three-strand p-sheet, but there are 
two a-helices (a-P-p-P-a), which is also similar to the RRM domain(49). When binding 
to dsRNA, the dsRBD binds to the face of the dsRNA helix, across two successive minor 
grooves and the major groove between, with no specific nucleobase interactions (50).
This binding interaction occurs at a cleft in the domain between the second a-helix and 
the p-sheet, with most of the contacts dependent on the 2'-hydroxyl (-OH) groups and
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phosphate backbone, which is unlike the RRM or KH domains (50). Although the 
dsRBD does not recognize specific nucleobase interactions, multiple dsRDBs can confer 
structure specificity as they could recognize different arrangements of helices. There are 
also some dsRBD having an N-terminal helix, which binds to bulges, stem-loops and 
irregular A-form RNA helices adding to the binding diversity of dsRBDs (50).
The identification of the ribosomal protein SI led to the initial finding of the SI 
domain, and since then other RBPs containing the SI domain such as exo-nucleases have 
been identified (55). The SI domain has approximately 70 residues, which form a 5- 
stranded anti-parallel P-barrel capped with a 3jo helix (50). This capped P-barrel is 
similar to the oligonucleotide/oligosaccharide binding (OB)-fold superfamily, which also 
contains the RNA-binding cold-shock domain (50). In common with the OB-fold 
binding surface, the SI domain recognizes nucleic acids via two p-strands surrounded by 
several loops and is similar to the RRM domain, with the two-stranded p-sheet at the core 
and involving aromatic residues for base stacking with nucleic acids (50).
The PAZ and Piwi domains are an SI or OB-fold like P-barrel linked to a small 
aP domain, forming a clamp like structure and are 110 amino acids in length (50). Dicer 
and Argonaute proteins have PAZ and Piwi domains for positioning miRNA and aid in 
cleavage of the target strand in the RISC (50).
Zinc Finger motifs (ZFMs) are classically a DNA binding motif, but can also bind 
to RNA. The ZFM is classified on the residues responsible to coordinating a zinc ion, 
(e.g., Cys2His2, CCHH. Or CCCH, CCHC) and is usually present as multiple repeats in a 
protein. First identified in TFIIIA, with nine CCHH motifs, of which 3 interact with 5S 
RNA as a form of protein synthesis regulation (49). The TIS1 Id zinc-finger protein is an
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example of CCCH zinc finger motifs bound to AU-rich RNA elements (ARE) (49). The 
ZMF interact with RNA at two loops, using the same recognition helices found in motifs 
for recognizing DNA via hydrogen bonding directly to the major groove or Watson-Crick 
base pairs (49). The major groove of RNA is too narrow to accept the conventional 
recognition helix presented, so it is possible that distinct residues make DNA and RNA 
contacts, or RNA is severely distorted at the recognition site to allow access of the major 
groove (49).
From these different RBDs it is important to note that they are vastly 
outnumbered by the total number of individual RBPs due to the combination and 
arrangement of RBDs. One must also then keep in mind that many different nucleic acid- 
binding structures are also occasionally involved in protein-protein interactions.
1.4 The Coding Region Determinant Binding Protein (CRDBP)
The c-myc coding region determinant binding protein (CRDBP) was initially 
identified in mice based on its ability to stabilize c-myc mRNA upon binding to a specific 
coding region of the transcript named the coding region determinant (56).
Figure 3. The Annotation of Mus musculus CRDBP Coding Region from N- 
terminus to C-terminus. The entire sequence of M. musculus CRDBP coding region is 
577 amino acids. KH1 amino acid 199 to 248. KH2 amino acid 280 to 330. KH3 amino 
acid 409 to 458. KH4 amino acid 491to 541.
1.4.1 The Cellular Role of CRDBP as an mRNA-Binding Protein
CRDBP binds to the following mRNAs whose gene products have been 
implicated in cancer: c-myc, CD44, MITF, MAPK4, Gli-1, P-TrCPl, IGF-II, K-Ras, 
MDR-1 (30, 57-61). The working model is that CRDBP binds and shields these mRNAs
KH-l KH-2 KH-3 KH-4
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from endonucleolytic attack by endoribonuclease or miRNA, thereby prolonging half-life 
of the transcripts (29,41, 62-64).
As a proto-oncogene, c-myc, codes for the protein MYC, which acts as a 
transcription factor regulating cell proliferation and differentiation (65). The stabilization 
of c-myc mRNA by CRDBP ultimately results in increased c-myc mRNA translation in 
cancer cells (57, 61, 63, 66). One study shows that c-Myc promotes the transcription of 
CRDBP and with this stabilization action and promotion relationship, a positive feedback 
loop is an easy conclusion (67). Similarly, stabilization of CD44 mRNA by CRDBP leads 
to increased invadopodia and cell adhesion, as CD44 is a cell surface protein for cellular 
attachment to extracellular matrix components and cell-cell adhesion (43, 58, 65, 68).
The overexpression of CRDBP also results in suppression of apoptosis of cancer 
cells that prolongs the turnover rate of p-TrCPl (61). f-TrC Pl mRNA has a coding 
region which is bound by miR-183 and Argonaute-2 to facilitate the degradation of /?- 
TrCPl mRNA and down regulate the translation for Skpl-Cullinl-F-box protein 
(SCF)pTrCP1E3 ligase which is a regulatory part of the cell cycle. This miR-183 binding 
site can be disrupted and/or occupied by CRDBP causing oncogenesis and the 
suppression of apoptosis (29).
Insulin-like growth factor II (IGF-II) mRNA plays an important role in cell 
proliferation, and is well known in regulating the development o f breast cancer (69). 
Pacher et al found increased levels of IGF-II in breast cancer, and CRDBP interaction 
with IGF-II mRNA is a likely cause (69, 70). Using ELISA, increases in serum IGF-II 
was measured in MCF7 cells overexpressed with IGF-II indicating CRDBP regulates 
bioavailability and half-life of IGF-II circulation (70). Serum CRDBP in early-stage
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breast cancer in women was detected using ELISA (69). Multi-drug resistance cancer 
cells commonly occur due to the production of a membrane protein that functions as an 
efflux pump with protective properties (71). This membrane protein, P-glycoprotein is 
coded for by MDR-1 mRNA, which has similar affinity as c-myc RNA for CRDBP, with 
a Kd of 500 nM (61,71). Such affinity between CRDBP and MDR-1 mRNA was 
proposed to be the mechanism for the over expression of MDR1 and the multidrug 
resistance phenotype observed in cancer cells (61).
1.4.1 Proposed Model for CRDBP RNA Recognition and Binding
CRDBP’s implication in cancer is based on its binding/stabilizing interactions 
with various mRNAs and its measured levels within a wide range of cancers. Binding 
sites for CRDBP-mRNA are found in the coding regions of c-myc, fi-TrCPl, and MDR-1 
mRNAs and at the 3'-UTR of CD44 mRNA. Segments of the ZBP-1 structure, a 
homologous protein to CRDBP, have been determined using X-ray crystallography. The 
study illustrated the truncated KH3-4 domains of ZBP-1 as the key domains for binding 
P-actin RNA as opposed to truncated RRM 1-2 and KH1-2 domains (72).
The domains of many RNA binding proteins have been revealed through cDNA 
production of many hnRNPs indicating the K homology domain which shares identity 
with the VICKZ protein family and CRDBP (73). The common characteristic of most 
KH domains in RNA-binding proteins and this motif is the mechanism for RNA 
interaction is the Gly-X-X-Gly motif (74). The KH domain of NS1, an influenza virus 
protein, has a highly flexible loop comprising the same conserved G-X-X-G motif, which 
stiffens and stabilizes upon binding to RNA (74). The G-X-X-G motif, located between
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a-helices 1 and 2 acts a C-terminus and N-terminus cap for the helices providing flexible 
stability, which allows interaction with RNAs (75). The a-helices 1 and 2 provided by 
this cap has been visualized under X-ray crystallography {Lewis, 2000 #23}. The a-helix 
1 and P-sheet 2 of Nova-2 KH3 domain has been crystallized showing interaction with 
mRNA (54, 74). More importantly the interaction between the KH3 domain of Nova 2 
and mRNA is due to the G-X-X-G sequence, producing Watson-Crick type hydrogen 
bonding with 5-CA-3' after recognizing a 5'-UCAC-3' sequence of mRNA (54). By 
acting as a 5'-UG-3' sequence, the G-X-X-G motif binds to mRNA with a variant loop 
between P sheet 1 and the P' sheet that clamps the mRNA in place (54). However, the 
binding of each KH domain is very individualistic based on the location of the G-X-X-G 
sequence relative to the p sheets and a  helices and the properties associated with the p 
sheets and a helices. The two RRM’s did not demonstrate any contribution to the binding 
of the ZBP-1 to 3'-UTR of fi-actin, but that the anti-parallel pseudodimer conformation of 
KH3 and KH4 together are responsible for the binding based on EMSA assays of 
truncated ZBP-1 at each of the RRMs and KH domains (individually and in combination) 
(72).
Researchers demonstrated the importance of the KH34 didomain of Vgl RBP, the 
homologue of CRDBP in frogs, as a key component for binding and stabilizing 
interactions between Vgl RBP and Vgl mRNA{Git, 2002 #24}. By examining point 
mutations introduced at the KH3 and KH4 domains, separately and simultaneously, only 
simultaneous point mutations interrupted the binding interaction (76). Mutants of the 
KH1, KH2 and KH1-2 domains showed change in Vgl RBP abilities to bind RNA, but 
the single mutants (KH1 and KH2), and double mutant (KH1-2) did not have a large
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difference in binding reduction, suggesting these KH domains are not as required for 
RNA binding (76). Although it was shown that KH34 didomains have a better 
interaction with the fi-actin (for ZBP-1) and Vgl (for Vgl RBP) RNAs than the other 
domains together, and individually, these interactions might be mRNA specific and have 
different results with different mRNA (72, 76). This also suggests that no individual 
domain is absolutely necessary which is also seen with the conserved sequences in all of 
the KH domains. Producing truncated forms of the CRDBP homologues also greatly 
affects their tertiary structure and how the RRMs and KH domain interact as a whole, 
with high affinity interactions possibly requiring all of the KH domains.
1.4.2 CRDBP in Cancer
CRDBP is also known as IMP1 (Insulin-like growth factor II mRNA-binding 
protein) identified as an oncofetal protein (62, 63, 77,78). CRDBP is expressed during 
embryogenesis in Mus musculus and as IMP-1 in Homo sapiens in the developing 
epithelial, muscle and placental tissue. As this tightly regulated protein becomes 
unregulated, it is defined as an oncofetal protein, overexpressed de novo in various 
cancers and associated with aggression and invasiveness (62, 63, 67, 78).
One of the cancers implicated with CRDBP is colorectal carcinoma, with 46 of 78 
cases (59%) measuring high levels of CRDBP (25). Expression of CRDBP has been 
measured by Ioannidis et al in a wide variety of cancers, such as non-small cell lung 
cancer, breast carcinomas, chronic myelogenous leukemia, sarcomas, and mesenchymal 
solid tumors (67, 78, 79). Previous research has shown that CRDBP expression is present 
in 73% of 33 malignant tumors tested and 40% of 10 benign mesenchymal tumors (64).
In comparison to adjacent normal tissues, tissue from brain tumors, non-small cell lung
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carcinomas, malignant, and benign neuroepithelial tumors all had high expression of 
CRDBP (64). By understanding how CRDBP’s binds with various mRNA uncovers a 
biochemical mechanism of how those cancer overexpressing CRDBP can be targeted.
1.5 Microphthalmia-associated transcription factor (MITF)
1.5.1 Function of MITF
Microphthalmia-associated transcription factor (MITF) plays a role in the 
development, survival and function of melanocytes, retinal pigment epithelial cells, 
osteoclasts, mast cells as well as stem cells of the hair bulge. MITF is comprised of three 
main structural regions, (1): a Helix-Loop-Helix Motif, (2): a Leucine Zipper Motif, and 
(3): a Basic Motif. The Helix-Loop-Helix and Leucine Zipper motifs (bHLHzip)
(Regions 1 and 2) are critical for protein interactions and key for MITF to form 
homodimers or heterodimers with other transcription proteins. Once dimerized, the Basic 
Motif is the functional region of MITF, which recognizes and binds deoxyribonucleic 
acid (DNA), facilitating transcription (Figure 4).
Figure 4. Cartoon of MITF dimer in cyan and green with DNA in grey. Missing 
protein loops are shown by dotted lines. Adaptation from Pogenberg et al. 2012 (3).
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1.5.2 Expression of MITF
Hallmarks of melanoma are rapid and continuous cell division, increased cell 
pigmentation and cell migration. As a transcription factor, MITF is a master regulator of 
melanocyte development and an important oncogene in melanoma. Gene targets of 
MITF responsible for increased cell proliferation include T-box transcription factor 2 
(TBX-2), cyclin-dependent kinase-2 (CDK2) and B-cell lymphoma-2 (BCL-2).
TBX-2 is a transcription factor, which down regulates p21, resulting in a 
suppression of cell senescence. CDK-2 modulates cell cycle progression at the G-l/S 
transition and S-phase and correlates with melanoma growth. BCL-2’s role as an anti- 
apoptotic factor leads to sustained melanoma cell survival, by inhibiting apoptosis of 
mitochondria (80). The down regulation of BCL-2 with siRNA showed sensitization of 
melanoma cells resistant to apoptotic effects (81). MITF also regulates the transcription 
of tyrosinase (TYR), tyrosinase-related protein-1 (TYRP-1) and tyrosinase-related 
protein-2 (TYRP-2/DCT), which promotes the induction of melanin (82). The continual 
expression of MITF in melanoma cells results in melanocytes becoming melanoma, 
which exhibit uncontrolled cell proliferation, resistance to apoptosis and increase in cell 
pigmentation (melanin) (83).
The regulation of MITF protein production is considered to come from MITF 3'- 
UTR mRNA sequences which show high levels of conservation within vertebrate and 
longer in length than most mRNAs (84). The down regulation of MITF mRNA by miR- 
148 and miR-137 binding in the 3'-UTR has been demonstrated which further adds to the 
importance of the 3'-UTR in the regulation of MITF gene expression (84, 85). A 
mutation, loss of function or inability of miRNA to interact at the 3'-UTR of MITF
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mRNA is a likely cause of melanomagenesis. Cell line and developmental studies have 
shown that miRNA-340 has the ability to regulate MITF at the 3'-UTR and this regulation 
can be interrupted and blocked in the presence of CRDBP (30).
Aside from melanoma, MITF has not been linked to any other cancers. MITF is 
part of a larger family of bHLHzip transcription factors with TFE3, TFEB and TFEC
(86). Like Myc, as dimerizing transcription factors, TFE3 and TFEB have been linked to 
renal cell carcinoma, but MITF has only been shown to be associated with melanoma
(87).
1.6 RNA Folding: Pros and Cons
The secondary structure of RNA is a result of base pairing of the nucleotides in 
canonical (A:U, U:A, G:C, C:G) and non-canonical (A:A, G:U) manner. The base 
pairings result in features such as stems, loops, bulges, and in combination, stem-loops, 
pseudoknots, and internal bulges.
The organization of RNA secondary structure into three-dimensional space gives 
rise to tertiary structure (Figure 5). Examples include double-helix formation in stems, 
coaxial base stacking between helices, and GAAA tetraloop interactions all of which can 
divided into structural motifs with specific biological function.
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Figure 5. RNA Molecules and their predicted tertiary structures. Superimposed in 
silico predicted structures (blue) are superimposed onto experimental structures (gold), 
(a) a hairpin with internal loop (28SP), (b) a duplex with two bulges (1I9X), (c) the 
pseudoknot 1KPZ, (d) Hammerhead ribozyme RNA 1NYI, (e) tRNA 1J1U and (f) SRP 
RNA 1Z43. Adaptation from Zhao et al. 2012 (4).
The ribosome and spliceosome are examples of functional quaternary RNA structures, 
where several RNAs come together to perform a specific task. Investigating secondary 
and tertiary structure will be most beneficial for identifying common structural features, 
which may associate with protein. Determining quaternary structure will not be 
necessary, as quaternary structure is important for active RNA function such as 
ribozymes as opposed to structural binding features.
How RNA functions and is able to be bound by protein is dependent on its 
structure, and by gaining knowledge of RNA structure, function can be assigned. The 
binding of distantly related RNAs by protein suggests that it is not the primary structure
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that defines the RNAs ability to be bound by protein, but rather their secondary and 
tertiary structure (88).
Determining RNA secondary and tertiary structure can be divided into the 
categories of computational analysis and experimental probing. To increase the accuracy 
of RNA secondary structure by computational prediction to identify motifs for binding to 
protein domains, it is important to assess different RNAs that demonstrate similar 
function experimentally. This eliminates the possibility of primary structure as the 
feature for binding, and reinforces the notion that secondary and tertiary structure as the 
mechanism for binding. It is also worth noting that the single stranded regions of the 
RNA secondary structure is where specific RNA-protein interactions are more likely to 
occur, because those regions are free to interact with the protein. Three most common 
ways to predict RNA secondary structure in silico are, (i) “single sequence secondary 
structure prediction”, (ii) “align-then-fold” and (iii) “simultaneously folding and 
alignment” (89).
The “single sequence secondary prediction” model relies on the thermodynamic 
stability of the overall secondary structure by maximizing the number of base pairs and 
scoring each structure by the minimum free energy (MFE) associated (90). This method 
uses the Zucker-Steigler algorithm for generating the MFE and is used in programs such 
as MFOLD/UNAFo/d and KNAfold (91-94). Possible improvements in secondary 
structure prediction can come from a dynamic algorithm, control OLD, which uses 
experimentally determine parameters to determine the MFE in combination with 
probabilistic models (95). Sfold uses a Boltzmann distribution to assign probabilities of 
representative secondary structures, and then clusters similar motifs into ensembles (96).
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The MFE might not always be included, but Sfold allows manual addition of RNA 
structures (89). KNAkinetics provides emsembles of structures with assigned 
probabilities by taking into account how RNA comes into existence as an elongating 
strand (97). The program calculates secondary structure as the RNA sequence is 
growing to demonstrate how RNA is dynamic (89). Vienna+P calculates RNA 
secondary structure with a model that simulates the presence of general single stranded 
RNA binding proteins (93, 98). This model tries to account for in vivo protein 
interactions, which could alter the secondary structure of the RNA. These secondary 
structure prediction models, from a single sequence are a good starting point as an initial 
indicator of possible homologous RNA secondary structure (89).
Being able to compare multiple RNA sequences binding to the same protein can 
be accomplished with the “align-then-fold” and “simultaneously folding and alignment” 
methods. Sequences aligned with higher than 55% sequence identity produce consistent 
results with the “align-then-fold” method compared to the “simultaneously folding and 
alignment” method which performs better with sequence similarity of 50-60% or lower 
(89). When performing “simultaneously folding and alignment” algorithms on a set of 
sequences aligning below 50-60%, it is recommended that additional structural 
information is included when running the program to achieve accurate alignments (89).
QRNA is an “align-then-fold” algorithm using a hidden Markov based model to 
assess non-coding gene segments (99). By aligning two sequences with synonymous 
substitutions, the model identifies a coding region, and compares regions to identify 
conserved RNA secondary structure such as the presence of stems (99). RNAz utilizes an 
MFE algorithm in conjunction with known RNA motifs in sets of aligned sequences
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(100). A support vector machine (pattern recognition algorithm) is used to assign a 
conservation of secondary structure index, and allows for genome-wide searches of 
similar sequences (89, 100). The QRNA and RNAz “align-then-fold” methods assumes 
the aligned sequences are evolutionary related or homologous sequences, but this will not 
be the case when assessing RNA sequences of different genes which possibly possess 
similar secondary structure (89). CMFinder is the most advantageous model, finding 
motifs in sets of unrelated RNA sequences using covariance models (101).
Simultaneous folding and alignment methods are applicable for set of sequences 
below 55-60% similar identity using the Sankoff algorithm (102). FOLD ALIGN scans 
multiple sequences for local and global similarities in secondary structure after 
simultaneous alignment and prediction of secondary structure (103). Using pairwise 
connection, CARNAC, attempts to predict conserved secondary structure of homologous 
non-coding RNAs in three steps (104). Firstly CARNAC predicts all the possible stem 
structures, then compares those in a pairwise fashion to extract the most related structures 
and compiled them into stem graphs (104). Two unaligned RNA sequences secondary 
structure can also be aligned, predicted in a MFE manner, and then additional 
experimentally characterized constraints included using Dynalign (105).
Prediction of RNA tertiary structure would provide a wealth of information for 
determining how the binding of protein is associated. Generating three-dimensional 
structure requires the incorporation of primary, secondary and tertiary information. Being 
able to distinguish similar features between various RNAs would provide a vast amount 
of insight into understanding RNA-protein interaction. MC-FOLD/MC-SYM pipeline 
predicts tertiary structure of RNA from primary sequence (89, 106). The MCFOLD
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algorithm predicts secondary structure with all possible nucleotide cyclic motifs, which 
are then organized into building blocks (106). The building blocks are matched to a 
database of determined three-dimensional structures, and MC-SYM  then compiles all of 
the blocks to generate three-dimensional model (106).
Table 1. Comparing computational algorithms for RNA structure prediction.
Mfold/UNAFold MFE Simple/fast Accuracy
Web browser 1 sequence
RNAfold MFE Simple/fast Accuracy
Web browser 1 sequence
contraFOLD Probabilistic/Exp Dynamic model with Accuracy
erimentally increased accuracy 1 sequence
determined
parameters
Sfold Boltzmann Dynamic model Accuracy
statistical provides groupings of 1 sequence
ensemble/MFE structures which would
structures can be help identify protein
manually added binding sites
RNAkinetics MFE of local Provides ensembles of Accuracy: RNA
sequences structures with would fold as it is
probabilities made, then introns
Accounts for growing are cut
RNA 1 sequence
Vienna+P MFE in the Calculates probability Does not account
presence of for each nucleotide to biological data:
generalized bind protein in the Known Protein
ssRNA binding entire RNA domains or # of
proteins nucleotides to bind
protein
QRNA Compares -2 sequence limit.
synonymous vs. -Assumes sequences
compensatory are evolutionarily
mutations related.
RNAz Averaged MFE Provides structural -Assumes sequences
structures vs. conservation index are evolutionarily
individual MFE related.
structures
CMFinder Covariance Applicable to unrelated
29
Dynalign
FOLDALIGNM
CARNAC
Model 
Simultaneous 
alignment and 
prediction
Simultaneous 
alignment and 
prediction 
Folds RNA based 
on local and 
global alignments 
Simultaneous 
alignment and 
prediction
sequences 
Predictions can be 
constrained to 
experimentally 
determined base parings 
Good for sequence 
below 55-60% 
similarity 
Scans for common local 
motifs after folding 
>2 sequences 
Good for sequence 
below 55-60% 
similarity 
Good for sequence 
below 55-60% 
similarit
2 sequence limit
Assumes sequences 
are homologous
MC-FOLD/MC-
SYM
Folds secondary 
structure into 
building blocks 
then compares 
blocks to 
determined 3D 
structures
Uses primary 
information to generate 
secondary and 3D 
structure with 
experimentally 
determined structural 
motifs
Database of 3D 
structures possibly 
limited
Folding biases due to the nature of the folding program exists. Which parameters 
are considered or not, and how these different parameters are weighted, all contribute to 
certain biased outcomes. These biases are then further exemplified when RNA sequences 
are truncated, as the full sequence has a potential to from different in vivo than a mere 
segment of it. Lastly, it is not known the exact dynamics of RNA and, some RNA 
sequences could be very fluid and easily manipulated to take on multiple different forms, 
all of them present at the same time.
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1.7 Objectives of this Research
The goals of this thesis is to gain a better understanding of the molecular 
interaction between CRDBP and its target RNAs, MITF and c-myc, by examining: (i) the 
structure of target RNAs, and (ii) assessing the RNA-binding ability of KH variants of 
CRDBP in vitro and in vivo.
1.7.1 Characterizing the structure of RNA targets of CRDBP
The first aspect for understanding CRDBP’s interaction with RNA is to gain 
knowledge of the RNA structure that facilitates binding to CRDBP. By mapping out 
smaller regions of RNA bound by CRDBP allows for a starting point for finding 
commonality in how CRDBP selects RNA. Using computer software to model secondary 
and tertiary structure of the mapped RNA regions, I am aiming to provide more accurate 
information as to how CRDBP interacts with its targets RNA. As an additional tool, I 
also used Circular Dichroism Spectroscopy to study MITF and c-myc RNA to examine 
RNA structure and their dynamics upon association with CRDBP.
1.7.2 Characterizing the RNA-binding ability of the KH domains of CRDBP
The structure of CRDBP will be characterized in vitro and in cells by assessing
the RNA-binding profile of site-directed KH variants of CRDBP. In vitro 
characterization of CRDBP will consist of electromobility shift assays to assess the 
binding of various CRDBP KH variants to c-myc and MITF RNAs. The cell studies will 
be conducted by the expression and immunoprecipitation of CRDBP KH variants in 
HeLa cells, followed by quantification of c-myc, CD44 and fi-actin mRNAs by q-PCR.
In addition, I attempted to use zebra fish model as an in vivo model to determine if defect 
in CKDBP-MITF RNA interaction can lead to defect in pigmentation.
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Chapter 2- Characterizing the MITF, c-myc, MAPK4, and p-TrCPl RNAs that bind 
CRDBP
The goal of this Chapter is to further characterize the RNAs that bind CRDBP. 
Specifically, the aim is to determine the smallest regions of several RNAs that still have 
affinity for CRDBP. Mapping the smaller regions of RNA fragments that bind CRDBP is 
important for several reasons. Firstly, the smaller regions of RNA molecules that bind 
CRDBP are of interest because they provide an opportunity to be analyzed in silico. It is 
important to point out that most in silico methods that predict the secondary and tertiary 
structures of RNA molecules require input of smaller sized RNA molecules. Secondly, 
the knowledge of smaller RNA binders of CRDBP permits development of high- 
throughput fluorescent anisotropy method to screen for inhibitors of CRDBP-RNA 
interactions. Thirdly, the knowledge of smaller RNA molecules that bind CRDBP have 
led to the discovery of specific oligonucleotides that inhibit CRDBP-RNA interaction in 
vitro and suppress specific gene expression in cells as demonstrated for CD44 and GLI1 
RNAs (107, 108).
2.1 Methodology
2.1.1 Protein Purification of Recombinant CRDBP
2.1.1.1 Transformation
The appropriate pET28b plasmid (-100 ng) is transformed into BL21 competent 
E. coli (100 pL). The BL21 competent E. coli 100 jxL aliquot is first thawed on ice from 
-80°C, and then incubated on ice with approximately 100 ng of corresponding plasmid 
for 30 minutes. The cells are then heat shocked for 90 seconds at 42°C and then 
incubated on ice for 1 minute. The cells are then incubated for 30 minutes at 37°C in 500
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nL LB broth and plated on LB-kanaraycin agar 10 mL dishes. The LB-kanamycin agar 
plates are then incubated at 37°C for 16 hours.
2.1.1.2 Induction
From the LB-kanamycin plate, 20 colonies are picked, inoculated into 100 mL of 
LB-Kanamycin broth in a 250 mL flask and placed in an incubator shaker at 37°C with 
200rpm for 3 hours. The 100 mL culture is then transfers into a 3 L flask, with 900 mL 
of LB-kanamycin and grown to an optical density of 0.5 (-2.5 hours). Upon reaching an 
optical density of 0.5, induction of protein was initiated with the addition of 0.3mM 
isopropyl-(3-D-thiogalactopyranoside (IPTG) (Invitrogen), and incubated on a shaker for 
6 hours, at 37°C and 200 rpm. The cells are then spun at 3000 rpm for 15 minutes at 4°C, 
with the supernatant removed and the pellets stored at -80°C overnight.
2.1.1.3 Purification
The cell pellets stored at -80°C were retrieved, thawed on ice, and resuspended in 
12 mL of buffer B (Table 2). The solution was kept on ice and placed on a shaker for 1 
hour of gentle mixing, followed with centrifugation at 13,200rpm, 4°C for 30 min. The 
cell lysate was then syringed filtered (0.45 pm filter) and mixed with lmL of nickel-NTA 
resin that had been washed with 5mL of H2O and 5mL of buffer B (Table 2). The 
filtered-lysate and Ni-NTA mixture is then placed on a bench-top plate shaker with ice 
for 1 hour. The resin and lysate suspension was pipetted back into the column, washed 
with 5 mL of buffer B, C, and D, while collecting 1 mL fractions (Table 2). The protein 
was then eluted with 12 mL of buffer E and F, collected in 0.5mL fractions. All the 
collected fractions were then stored at -80°C, and the column was washed with 6 mL of 
0.5M NaOH, 10 mL of H2O, capped with 30% ethanol and stored at 4°C.
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2.1.1.4 12% SDS-PAGE of Purified CRDBP Protein Fractions
A BioRad Mini-Protean System was used to prepare 0.75 mm 12% SDS-PAGE 
gels, and have them electrophoresed at 240 V in IX Tris-Glycine running buffer (Table 
2). O f selected fractions from each of the CRDBP variants, 16 pL were boiled for 5 
minutes with 4 pL of 5X sample buffer and allowed to cool for 1 minute prior to being to 
loaded (Table 2). Following electrophoresis, the gels were stained with Coomasie blue 
dye for 1 hour, destained overnight and imaged (Table 2).
2.1.2 Dialysis of Isolated CRDBP Protein
The isolated fractions of purified CRDBP protein contained 8 M urea, 0.1 M 
NaH2PC>4 , 0.01 M Tris-Cl; pH 4.5/5.9 was dialyzed in a two-step gradient to remove urea, 
normalize pH and alter buffer concentrations (Table 2). Slide-A-Lyzer® MINI dialysis 
units (3,500 MWCO, from Thermo Scientific) were loaded with a maximum of 100 pL 
(-60 ng) of CRDBP variant and placed in a beaker with 50 mL of dialysis buffer A for 26 
hours at 4°C. The mini dialysis units are then transferred into dialysis buffer B for 2 
hours at 4°C, and then transferred again into a new beaker of 200 mL dialysis buffer B 
for 2 hours at 4°C. The dialyzed CRDBP protein was then pipetted into a 1.5mL 
microcentrifuge tube, centrifuged at 13,200 rpm for 30 minutes at 4°C, and supernatant 
transferred to a new 1.5 mL microcentrifuge tube and stored at 4°C (centrifugation was to 
remove any large aggregates). The concentration of protein was determine using BCA™ 
Protein Assay Kit (Pierce, IL, U.S.A.).
2.1.3 Generation of Internally Radiolabelled RNA
Radiolabeled RNA was prepared using 32P-UTP and corresponding cDNA 
templates. The template DNA is incubated with 32P-UTP, IX transcription buffer, 20
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Umol DDT, 20U rRNasin, 1 pmol each of ATP, GTP, CTP, 10 nmol UTP and 30 UT7- 
RNA polymerase to a final volume of 20 pL for 30 minutes at 37°C. Next lOpL of RQ1 
(1 U/pL, RNase free DNase) was added to each sample and incubated at 37°C for an 
additional 10 minutes. Then 10 pL of loading dye is added and electrophoresed at 25 mA 
for 1 hour on a 6% denaturing polyacrylamide gel (7 M Urea). The gel was imaged with 
a cyclone storage phosphor screen system, printed off and placed underneath the gel to 
excise the RNA transcripts. The excised transcripts are crushed with an eppendorf pestle 
and eluted in 400pL of DEPC water for 10 minutes at 70°C. The elution is followed with 
removal of the gel using Performa® DTR Gel Filtration Cartridges (EdgeBio, MD,
U.S.A) a standard phenol/chloroform extraction and an ethanol precipitation. The 
precipitated RNA is resuspended in 30 uL of ddH20  and 2 pL is placed in 1 mL of 
scintillation fluid and the radioactivity is measured on a Hidex liquid scintillation 
analyzer in counts per minute (cpm), then stored at -20°C.
2.1.4 Electrophoretic Mobility Shift Assays (EMSA)
Prior to each shift assay, the required EMSA binding buffer was prepared on ice, 
and the EMSA reaction mixture was pipetted. Internally radiolabeled RNA samples were 
refolded by heating each sample to 50°C for 5 minutes and cooling at room temperature 
for 7 minutes, and then 2 pL of RNA was added to each of the reaction tubes. The 
dialyzed CRDBP protein was then incubated in the EMSA binding buffer containing the 
internally radiolabeled RNA alternating twice between 3 5 °C for 10 minutes, followed 
incubation on ice for 5 minutes. The binding reaction had 2 pL of loading dye added and 
15 pL loaded onto a 4% non-denaturing polyacrylamide gel electrophoresed at 25 mA for 
55 minutes (Table 2). The gel was then transferred onto chromatography paper, wrapped
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in plastic-wrap, and exposed overnight on a phosphor imager screen. Cyclone Storage 
Phosphor Screen System and Optiquant software was used to image the exposed 
phosphor screen and generate the autoradiographs.
Table 2. Reagents used in the purification, analysis, dialysis and EMSA protocols of 
6xHIS CRDBP.
Reagent Identity Reagent Composition
Buffer C (Wash) 8 M Urea, 0.1 M NaH2P 04, 0.01 M Tris-Cl; H 6.5.
Buffer E (Elution) 8 M Urea, 0.1 M NaH2P 04, 0.01M Tris-Cl; H 5.9.
12% SDS-PAGE Lower gel
12% Acrylamide, 0.3% Bis-acrylamide, IX 
Lower gel buffer, 0.04% Ammonium per 
sulfate, 0.06% TEMED.
Lower gel buffer 18% (w/v) Tris-base, 0.4% (w/v) Sodium Dodecyl Sulfate, pH 8.8.
Tris-Glycine Running Buffer 0.3% (w/v) Tris-base, 1.44% (w/v) Glycine, 0.1% Sodium Dodecyl Sulfate.
Coomassie Blue dye 
Dialysis Buffer A*
0.1% (w/v) Coomassie Blue.
2 M Urea, 1 mM L-glutathione reduced, 
0.1 mM L-glutathione oxidized.
Loading Dye
9 M Urea, 0.01% Bromophenol Blue, 
0.01% Xylene cyanole FF and 0.01% 
Phenol.
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lOx Glycogen 0.2 mg/ml Glycogen and 3M Sodium 
Acetate
EMSA Binding Buffer
EMSA Loading Dye
50 mM Tris-Cl (pH 7.4), 12.5 mM EDTA 
(pH 8.0), 10 mM DDT, 25% Glycerol, and 
0.01% Triton X -100.
250 mM Tris-Cl (pH 7.4), 0.2% 
Bromophenol Blue, 0.2% Xylene cyanol, 
and 40% Sucrose.
* Each Dialysis buffer contains a solution of 200 mM sodium chloride (NaCl), 20 mM 
Tris (pH 8.0), 10% (v/v) glycerol, 0.01% (v/v) Triton X-100, pH 7.4
2.2 Results
All four RNA fragments, MITF, c-myc, MAPK, and P-TrCPl and their regions of 
interest were chosen based on findings reported in the literature. The goal was then to 
find the smallest fragments of each RNA that could still bind to CRDBP. However, the 
first step was to generate DNA fragments corresponding to the desired RNA fragments 
using PCR. The primers used in the PCR encoded the T7 promoter region are shown in 
Tables 7 to 10. The amplified DNA templates were then used for 32P-UTP in vitro 
transcription reaction to generate the radiolabelled RNA for use in the EMSAs.
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Table 3. List of primers used for PCR to generate MITF DNA templates for in vitro
transcription._______________________________________________________________
Primer
MITF Forward 1550
Primer Sequence
5' GGA TCC TAA TAC GAC TCA CTA TAG G 
ATT GTA CAA ATA AGT GTG 3'
MITF Reverse 1740
MITF Forward 1621
MITF Forward 1701
5' TGG TTG CTT TAC ATT CTT 3'
5' GGA TCC TAA TAC GAC TCA CTA TAG G 
TTT GCG TCA GAG AAA TGT 3’
5' GGA TCC TAA TAC GAC TCA CTA TAG G 
ATC AAA TGT AAA GTT TAA 3'
MITF Reverse 1619 5' TCC TCT TGC TCA GAA AGC 3'
MITF Reverse 1709 5’ ACA TTT GAT TTC CAA GGA 3’
Underlined is the SP7 promoter sequence.
Table 4. List of primers used for PCR to generate c-myc DNA templates for in vitro 
transcription.______________________________________________________________
Primer
c-myc Forward 1735
c-myc Forward 1815
c-myc Reverse 1744
c-myc Reverse 1886
Primer Sequence
5’ GGA TCC TAA TAC GAC TCA CTA TAG G 
AGG CCC CCA AGG TAG TTA 3’
5' GGA TCC TAA TAC GAC TCA CTA TAG G 
GAA GAG GAC TTG TTG CGG 3'
5’ TTG GGG GCC TTT TCA TTG 3'
c-mvc Reverse 1814 5’ AGA AAT GAG CTT TTG CTC 3
5' CGC ACA AGA GTT CCG TAG 3'
Underlined is the SP7 promoter sequence.
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Table 5. List of primers used for PCR to generate MAPK DNA templates for in vitro
transcription._______________________________________________________________
Primer
MAPK Forward 3071
MAPK Forward 4368
MAPK Reverse 3754
Primer Sequence
5' GGA TCC TAA TAC GAC TCA CTA TAG G 
TCT TGC AGA GGT AGC TCC 3'
5' GGA TCC TAA TAC GAC TCA CTA TAG G 
GCA AAC TAT AAT TTG TAC 3'
5' GTC TGG AGA GGC GCT GTG 3'
MAPK Reverse 3424 5' ATG CTT GGT GAC TAG GAG 3'
MAPK Reverse 4386 5’ TGA TTA GAT TTA AGG TGC 3'
Underlined is the SP7 promoter sequence.
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Table 6. List of primers used for PCR to generate p-TrCPl DNA templates for in
vitro transcription.________________________________________________________
Primer Primer Sequence
p-TrCPl Forward 661 5’ GGA TCC TAA TAC GAC TCA CTA TAG G ACC TGA AGC CCA TGT TGC 3'
p-TrCPl Forward 1021 5’ GGA TCC TAA TAC GAC TCA CTA TAG G TGC AGA GGA TTC AGT GCC 3’
-TrCPl Reverse 678 5' GCA ACA TGG GCT TCA GGT 3’
-TrCPl Reverse 1040 5' GCG GCA CTG AAT CCT CTG 3’
-TrCPl Reverse 1372 5’ ATG TCC CAC ACA GCA ATG 3'
P-TrCPl Forward 1091 5' GGA TCC TAA TAC GAC TCA CTA TAG G TAT CAG TGG CCT ACG AGA 3'
5' CAG ACA GAG GAC AGA GCC 3'TrCPl Reverse 1190
P-TrCPl Reverse 1110 5' TAT CTC GTA GGC CAC TGA 3’
Underlined is the SP7 promoter sequence.
2.2.1 MITF
Determining the smallest region of MITF RNA best bound by CRDBP began with 
a literature search which indicated that CRDBP binds MITF mRNA within the 3-UTR, 
which spans nucleotides 1261-1822 (30). Nucleotide (nt) 1330 was chosen as the start 
site because Goswami et al has noted miRNA-340 first binding site, which spans nts 
1444 to 1464 (marked in bold in Figure 2D of Goswami et at), and hence the start of nt 
1330 would encompass the miRNA binding sites (30). The 3'-UTR region of MITF RNA 
from nts 1330 to 1740 were selected for RNA mapping studies. The two miRNA-340 
and miR-548c-3p sites located close to the 3'-end of the 3'-UTR are critical as these are
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the only sites likely to be present in both melanoctyes and melanoma. The miRNAs are 
expected to be blocked from binding to the MITF RNA due to binding of CRDBP (30). 
Goswami et al noted that the shorter RNA isoforms are present in melanoma cells, hence 
nt 1740 was chosen as the end point of the MITF RNA in the RNA mapping studies (30).
The MITF region of 1330-1740 was initially divided into two regions, 1330-1550 
(211 nts) and 1550-1740 (191nts). The two portions of MITF’s 3'-UTR (1330-1550 and 
1550-1740) were compared alongside with c-myc RNA nts 1705-1886 which served as a 
positive control. From Figure 6, it is clear that both MITF RNA fragments bind CRDBP. 
It is also clear that MITF nts 1550-1740 had a greater affinity (Figure 6).
C-myc M IT F  1330-1550 M IT F  1550-1740
C R D  BP: ss ^  ^  ^
Bound £
Unbound -
1 2  3 4 5 6 7 8 9 10 11 12 13 14
Figure 6. Electrophoretic Mobility Shift Assay of recombinant CRDBP with MITF 
RNA fragments (1330-1550 and 1550-1740) and c-myc 1705-1886.
[32P] RNA (20,000 cpm/reaction) incubated with varying concentrations of CRDBP as 
shown. Samples were electrophoresed in a 4% native polyacrylamide followed by 
autoradiography.
The higher affinity 1550-1740 MITF fragment was then further divided into eight 
fragments of decreasing length from the 3' and 5'-end (Table 7) using the PCR 
amplification. The PCR-amplified DNA templates were then used in the in vitro 
transcription reaction to produce the radiolabelled RNA fragments for use in EMSA 
binding assays (Figure 7).
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Table 7. MITF RNA fragments assessed for binding with recombinant WT-CRDBP
RNA Fragment 
Nucleotide Composition
A C G U
D M A  17 A R N ARNA Fragment .
Identity Fragmen‘Length
RNA Fragment’s 
affinity for CRDBP*
MITF 1330-1550 221nts 62 43 28
MITF 1550-1709 160nts 45 25 34
MITF 1550-1619
MITF 1581-1740 152nts 50 25 32
MITF 1671-1740
Data is from Figures 8 to 11.
(++++), (+++), (++), and (+) Indicate -90%, -70%, -40% and -10% binding 
respectively. (+/-) and (-) Indicate weak and no protein-RNA complex was visualized.
D
MITF
1330-1550
MITF
1550-1740 y  y  y  yMITF MITF MITF 1550-1740 1581-1740 1671-1740
1 2 3 4
B
MITF MITF MITF 
1550-1740 1550-1709 1550-1669 1 2  3 4 5 6
1 2 3 4
Figure 7. In vitro transcription of 32P-UTP labeled MITF RNAs. PCR-amplified 
DNAs were used as templates for in vitro transcription to generate MITF RNA 
fragments. (A) nts 1330-1550 and 1550-1740. (B) 1550-1740,1581-1740, and 1671- 
1740. (C) 1550-1619,1550-1589,1671-1740, and 1701-1740. (D) 1550-1740,1550- 
1709, and 1550-1669. RNA samples were then electrophoresed in a 6% denaturing 
polyacrylamide gel followed by autoradiography.
From EMSAs of these MITF RNA fragments, nts 1550-1709, 1550-1669, 1581- 
1740, and 1621-1740 all showed binding affinity for CRDBP (Figure 8, 10 and 11). In 
contrast, MITF RNA fragments 1550-1619, 1550-1589, and 1701-1740 did not exhibit
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binding affinity for CRDBP (Figures 9 and 11). MITF fragment 1671-1740 showed 
weak affinity for CRDBP (Figure 11).
M IT F  1550-1740 M 1TF1550-1709
CRD-BP: *  ^
' [Bound
Unbound -
10 11 12
M IT F  1550-1669
1 1 1
13 14 15 16
Figure 8. Electrophoretic Mobility Shift Assay of recombinant CRDBP with MITF 
RNA fragments. [32P] MITF RNAs (20,000 cpm) nts 1550-1740, 1550-1709, and 1550- 
1669 were incubated with varying concentrations of CRDBP as shown. Samples were 
electrophoresed in a 4% native polyacrylamide followed by autoradiography.
M IT F  1550-1740 M IT F  1550-1589M IT F  1550-1619
Bound
Unbound
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Figure 9. Electrophoretic Mobility Shift Assay of recombinant CRDBP with MITF 
RNA fragments. [32P] MITF RNAs (20,000 cpm) nts 1550-1740,1550-1619, and 1550- 
1589 were incubated with varying concentrations of CRDBP as shown. Samples were 
electrophoresed in a 4% native polyacrylamide followed by autoradiography.
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CRD BP: *
Bound
Unbound -
A l1®
V
.«*V
a 14»
Figure 10. Electrophoretic Mobility Shift Assay of recombinant CRDBP with MITF 
RNA fragments. [ 2P] MITF RNAs (20,000 cpm) nts 1550-1740 and 1581-1740 were 
incubated with varying concentrations of CRDBP as shown. Samples were 
electrophoresed in a 4% native polyacrylamide followed by autoradiography.
CRD BP: ft ft ft nM
Bound £
Unbound -
I
1 2 3 4 5 8 9 10 11 12
Figure 11. Electrophoretic Mobility Shift Assay of recombinant CRDBP with MITF 
RNA fragments. [32P] MITF RNAs (20,000 cpm) nts 1621-1740,1701-1740, and 1671- 
1740 were incubated with varying concentrations of CRDBP as shown. Samples were 
electrophoresed in a 4% native polyacrylamide followed by autoradiography.
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CRD-BP
Binding
1550----------------------------------- 1740 191nts ++++
1550------------------------------ 1709 160nts ++++
1550----------------------- 1669 120nts ++
1550-----------------  1619 70nts -
1550 ■---------1589 40nts -
1581 ----------------------------------  1740 152nts ++++
1621--------------------------  1740 112nts ++++
1.67!-------------------  1740 72nts +/-
1701 1740 42nts
Figure 12. Summary of MITF RNA fragments and relative binding affinity for
CRDBP. The region of interest is shown in blue and the smaller fragments are shown in 
black. (++++), (+++), (++), and (+) indicate -90%, -70%, -40% and -10% binding 
respectively. (+/-) and (-) indicate weak and no protein-RNA complex respectively.
2.2.2 c-myc
The 182 nts c-myc fragment of nts 1705-1886 was originally shown by Doyle et 
al to be bound with high affinity to CRDBP (56). This region was even further narrowed 
down to 1705-1792, an 88 nt fragment (56). Additional research by Mr. Dan Sparanese 
in Dr. Lee’s Lab also indicated that c-myc nts 1705-1886 as an excellent binding partner 
of CRDBP (61). This 1705-1886 CRD region of c-myc was therefore further truncated 
from the 5' and 3' ends into eight DNA fragments by PCR method. The PCR-amplified 
DNA templates were then in-vitro transcribed using radiolabelled UTP to produce the 
RNA fragments (Table 8, Figures 13 and 14).
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Table 8. c-myc RNA fragments examined by EMSA for interaction with CRDBP
RNA RNA Fragment
RNA Fragment Nucleotide Composition Fragment’s
Identlt* Length A C G U ^affinity for CRDBP*
c-myc 1705-1886 ++++182nts 43 42
c-mvc 1705-1814 llOnts 39 29 22 20
c-mvc 1705-1744
26 28 22c-mvc 1775-1886 112nts
c-mvc 1845-1886
“Data is from Figures 15 to 19.
(++++), (+++), (++), and (+) Indicate ~90%, -70%, -40% and -10%  binding 
respectively. (+/-) and (-) Indicate weak and no protein-RNA complex was visualized.
C-myc C-myc C-myc C-myc C-myc
1705-1886 1705-1854 1705-1814 1705-1792 1705-1744
1 2  3 4  5 6 7 8  9 10
Figure 13. In  vitro transcription of 32P-UTP labeled c-myc RNA Fragments. PCR- 
amplified DNAs were used as templates for in vitro transcription to generate c-myc RNA 
fragments nts 1705-1886, 1705-1854, 1705-1814, 1735-1792, and 1705-1744. RNA 
samples were then electrophoresed in a 6% denaturing polyacrylamide gel followed by 
autoradiography.
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C-myc C-myc C-myc C-myc C-myc 
1705-1B86 1735-1886 1775-1886 1815-1886 1845-1886
1 2  3 4  5 6 7 8  9 10
Figure 14. In  vitro transcription of 32P-UTP labeled c-myc RNA Fragments, PCR- 
amplified DNAs were used as templates for in vitro transcription to generate c-myc RNA 
fragments nts 1705-1886, 1735-1886, 1775-1886, 1815-1886, and 1845-1886. RNA 
samples were then electrophoresed in a 6% denaturing polyacrylamide gel followed by 
autoradiography.
The c-myc fragments of 1705-1854,1705-1814,1705-1792, and 1735-1886, all 
demonstrated high affinity binding with CRDBP in EMSA (Figures 15, 16, and 17). The 
c-myc RNA fragments 1735-1792,1775-1886, 1815-1886, also exhibited binding with 
CRDBP although with much reduced affinity (Figures 16, 17 and 18). In contrast, c-myc 
RNA fragment 1705-1744 and 1845-1886 did not show any interaction with CRDBP 
(Figures 16 and 17).
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C-myc 1705-1886 C-myc 1705-1854 C-myc 1705-1814
Bound
Unbound
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Figure 15. Electrophoretic Mobility Shift Assay of recombinant CRDBP with c-myc 
RNA fragments. [ P] c-myc RNAs (20,000 cpm) nts 1705-1886, 1705-1854, and 1705- 
1814 were incubated with varying concentrations of CRDBP as shown. Samples were 
electrophoresed in a 4% native polyacrylamide followed by autoradiography.
C-myc 1705-1886 C-myc 1705-1792______________ C-myc 1705-1744
Bound
Unbound
Unbound
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Figure 16. Electrophoretic Mobility Shift Assay of recombinant CRDBP with c-myc 
RNA fragments. [32P] c-myc RNAs (20,000 cpm) nts 1705-1886, 1705-1792, and 1705- 
1744 were incubated with varying concentrations of CRDBP as shown. Samples were 
electrophoresed in a 4% native polyacrylamide followed by autoradiography.
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C-myc: 1705-1886 1735-1886 1775-1886 1815-1886 1845-1886
C RD  BP: *  A * $  * av  ^  *  Av & * A* $  * A * $  „m
Bound £
Unbound -
Figure 17. Electrophoretic Mobility Shift Assay of recombinant CRDBP with c-myc 
RNA fragments. [ P] c-myc RNAs (20,000 cpm) nts 1705-1886, 1735-1886, 1775- 
1886, and 1845-1886 were incubated with varying concentrations of CRDBP as shown. 
Samples were electrophoresed in a 4% native polyacrylamide followed by 
autoradiography.
C-myc: 1735-1886 1775-1886 1735-1792 1815-1886 1845-1886
C RD -BP: *  A * $  * A^ &  *  A * $  *  A * nM
Bound £
Unbound -
1 2 3 4 5 6 2 8 9 10 11 12 13 14 15 16 17 18 19 20
Figure 18. Electrophoretic Mobility Shift Assay of recombinant CRDBP with c-myc 
RNA fragments. f 2P] c-myc RNAs (20,000 cpm) nts 1735-1886, 1775-1886, 1735- 
1792, 1815-1886, and 1845-1886 were incubated with varying concentrations of CRDBP 
as shown. Samples were electrophoresed in a 4% native polyacrylamide followed by 
autoradiography.
An additional smaller c-myc RNA fragment nts 1735-1792 (58 nts) could also be 
synthesized. This fragment was truncated from both the 5'-end and 3'-end and has the 
possibility of interacting with CRDBP. Furthermore, analysis of this fragment would
ill
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help in narrowing down the smallest region of c-myc RNA that interacts with CRDBP. 
EMSA of c-myc RNA fragment 1735-1792 indicated that this fragment was indeed 
capable of binding to CRDBP (Figure 19). Another RNA fragment smaller than the 182 
nts c-myc fragment 1705-1886 that indicated binding to CRDBP was 1815-1886 (72 nts) 
(Figures 17 and 18).
A  B
Cmy* C-ayr: 1735-1886 1775-1886 1735-1792
1735-1792
CRD-BP: % A* ^  &  n S f
I 2 Bound[
I  J  I  AmAA
1 £ 3 4 $ 6 ? »  9 10 11 12
Figure 19. In  vitro transcription of 32P-UTP labeled c-myc RNA Fragm ent and 
Electrophoretic Mobility Shift Assay of recombinant CRDBP. (A) PCR-amplified 
DNA used as templates for in vitro transcription to generate c-myc RNA fragment nts 
1735-1792. RNA samples were then electrophoresed in a 6% denaturing polyacrylamide 
gel followed by autoradiography. (B) [32P] c-myc RNAs (20,000 cpm) nts 1735-1886, 
1775-1886, and 1735-1792 were incubated with varying concentrations of CRDBP as 
shown. Samples were electrophoresed in a 4% native polyacrylamide followed by 
autoradiography.
50
CRD-BP
Binding
1705- —  1886 182nts ++++
1705- 1854 150nts ++++
1705-------------------------- Ig l4 HOnts +++
1705------------------ 1792 88nts +++
1705 ■--------- 1744 40nts -
1735 ----  1886 152nts +++
17 7 5---------------------- ----  1886 112nts ♦/-
1 8 1 5 --------------- ----  1886 72nts +/-
1845 ------ 1886 42nts
1735------------------  1792 58nts +/-
Figure 20. Summary of c-myc RNA fragments and their relative binding affinity for
CRDBP. The region is interest is shown in blue and the smaller fragments are shown in 
black. (++++), (+++), (++), and (+) Indicate -90%, -70%, -40% and -10% binding 
respectively. (+/-) and (-) Indicate weak and no protein-RNA complex was visualized.
2.2.3 MAPK4
Stohr et al 2012 were the first to discover that IGF2BP1 (IMP-1) inhibited 
MAPK4 expression by interfering with mRNA translation upon associating with the 
MAPK4 3-UTR (59). The MAPK4 nucleotide sequence was then identified on NCBI as 
Homo sapiens mitogen-activated protein kinase 4 (MAPK4) mRNA (NCBI Reference 
Sequence: NM 002747.3) and the 3'-UTR region spanning nucleotide 2765 to 4736, with 
a poly A signal starting at 4713. The 3'-UTR region for mapping MAPK4 RNA was then 
selected from nucleotide 2764 to 4713 (1949 nts). The MAPK 2764-4713 (1949 nts)
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region was divided into six fragments of -340 nts in length. RNA Fragments 3071-3424
(354 nts) and 3403-3754 (352 nts) could not be generated. This reason is not clear for
either 3071-3424 (354 nts) or 3403-3754 (352 nts), but 3403-3754 (352 nts) does have a
higher number of cytosine at 141 than the rest (Table 9). The remaining four RNA
fragments, 2764-3089 (326 nts), 3723-4063 (341 nts), 4036-4386 (351 nts), and 4368-
4713 (346 nts) were successfully transcribed (Table 9 and Figure 21).
Table 9. MAPK4 RNA fragments examined by EMSA for interaction with CRDBP.
RNA RNA Fragment Nucleotide RNA Fragment’s 
Fragment Composition affinity for
Length A C G U CRDBP*
RNA Fragment 
Identity
MAPK4 2764-3089 326nts
MAPK4 3403-3754 352nts
MAPK4 4036-4386 351nts
74 87 109 56
73 141 59 79
++++
N/A
“Data is from Figure 22.
(++++), (+++), (++), and (+) Indicate -90%, -70%, -40% and -10% binding 
respectively. N/A indicates the binding affinity could not be assessed because the RNA 
fragments could not be generated.
M A P K  M A P K  
2764-3089 3071-3424
M A P K  M A P K  M A P K  M A P K  
3403-3754 3723-4063 4036-4386 4368-4713
3 4 5 6 7 8  9 10 11 12
Figure 21. In  vitro transcription of 32P-UTP labeled MAPK RNA Fragments. PCR-
amplified DNAs were used as templates for in vitro transcription to generate MAPK
RNA fragments nts 2764-3089, 3071-3424, 3403-3754, 3723-4063, 4036-4386 and 4386-
4713. RNA samples were then electrophoresed in a 6% denaturing polyacrylamide gel
followed by autoradiography.
The four successfully transcribed shorter RNA fragments of MAPK (2764-3089,
3724-4063,4036-4386 and 4368-4713) were found to bind CRDBP effectively (Figure
22).
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P -T rC P l M A P K  M A P K  M A P K  M A P K
1021-1219 2764-3089 3723-4063 4036-4386 4368-4713
Bound
Unbound
Figure 22. Electrophoretic Mobility Shift Assay of recombinant CRDBP with 
MAPK RNA fragments. [32P] MAPK RNAs (20,000 cpm) nts 2764-3089, 3723-4063, 
4036-4386,4368-4713, and P-TrCPl 1021-1219 were incubated with varying 
concentrations of CRDBP as shown. Samples were electrophoresed in a 4% native 
polyacrylamide followed by autoradiography.
CRD-BP
Binding
2764 — 4713 1950nts
2764 — ------ 3089 326r>ts ++++
3071------—  3424 354nts N/A
3403 — ----- 3754 3S2nts N/A
3723 ----- —  4063 341nts ++++
4036 — -----4386 351nts ++++
4368----- —  4713 346nts
Figure 23. Summary of MAPK RNA fragments and their relative binding affinity 
for CRDBP. The region is interest is shown in blue and the smaller fragments are shown 
in black. (++++), (+++), (++), and (+) Indicate ~90%, ~70%, -40% and -10% binding 
respectively. N/A indicates the binding affinity could not be assessed.
2.2.4 p-TrCPl
Noubissi et al 2006 were the first to describe the ability of CRDBP to stabilize the 
577-1182 (606 nts) region of P-TrCPl RNA (60). Elcheva et al 2009 then further 
described the stabilization and protection of P-TrCPl RNA (nts 577-1182) by CRDBP, 
regulating the RNA in miRNA-dependent manner by interrupting Argonuate2 and
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miRNA-182 (29). Having established nucleotides 577-1182 as the important region of (3- 
TrCPl RNA for interaction with CRDBP, the regions of 510-1372 (863 nt) were then 
selected and split into five smaller regions to ensure full coverage (Table 10).
Table 10. P-TrCPl RNA fragments examined by EMSA for interaction with 
CRDBP.
RNA Fragment 
Identity
RNA RNA Fragment Nucleotide
fragment Composition RNA Fragment’s
ragmem f affinity for CRDBP*
Length A C G U J
TrCPl 510-678 169nts
TrCPl 853-1040 188nts
TrCPl 1203-1372 170nts 46 48
TrCPl 1021-1150 130nts
169ntsTrCPl 1051-1219 ■H—H
P-TrCPl 1131-1219 89nts 24 18 23 24
“Data is from Figures 26, 27, 29 and 30.
p-TrCPl nts 510-678 and 661-862 were initially analyzed in Dr. Lee’s lab (Mackedenski 
S, unpublished data). (++++), (+++), (++), and (+) Indicate -90%, -70%, -40% and 
-10%  binding respectively. (+/-) and (-) Indicate weak and no protein-RNA complex 
was visualized.
P-TrCPl RNA fragment 510-678 (169 nts) and 661-862 (202 nts) were previously 
analyzed in Dr. Lee’s Lab to show that P-TrCPl RNA fragment 510-678 (169 nts) bound 
best to CRDBP (Table 10) (Mackedenski S, unpublished data). The next step was to in 
vitro transcribe and compare the 510-678 (169 nts) P-TrCPl RNA fragment with 853- 
1040 (188 nts), 1021-1219 (199 nts) and 1203-1372 (170 nts) (Figure 24).
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P-TVCP1 p-TYCPl p-TrCPl
661-862 853-1040 1021-1219
1 2 3 4 5 6
Figure 24. In  vitro transcription of 32P-UTP labeled p-TrCPl RNA Fragments PCR- 
amplified DNAs were used as templates for in vitro transcription to generate P-TrCPl 
RNA fragments nts 661-862, 853-1040, and 1021-1219 RNA samples were then 
electrophoresed in a 6% denaturing polyacrylamide gel followed by autoradiography.
P-TrCPl RNA fragment 1021-1219 (199 nts) was found to bind better than 510-
678 (169 nts), 853-1040 (188 nts) and 1203-1372 (170 nts) (Figures 25, 26 and 27).
CRD-BP
Binding
510 — -----1372 710nts
510 —--------678 169nts +++
661------ ---- 862 202nts ++
853-----------1040 188nts +++
1021-----------1219 199 nts ++++
1203------ ----1372 170nts ++
Figure 25. Summary of p-TrCPl RNA fragments and their relative binding affinity 
for CRDBP. The region of interest is shown in blue and the smaller fragments are shown 
in black. (++++), (+++), (++), and (+) Indicate -90%, -70%, -40% and -10%  binding 
respectively.
p TrC P l 510-678 p -T rC P l 1021-1219
Bound
Unbound
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Figure 26. Electrophoretic Mobility Shift Assay of recombinant CRDBP with 0- 
TrCPl RNA fragments. [32P] P-TrCPl RNAs (20,000 cpm) nts 510-678, and 1021- 
1219 were incubated with varying concentrations of CRDBP as shown. Samples were 
electrophoresed in a 4% native polyacrylamide followed by autoradiography.
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C R D B P :
Bound
Unbound
Figure 27. Electrophoretic Mobility Shift Assay of recombinant CRDBP with p- 
TrCPl RNA fragments. [32P] P-TrCPl RNAs (20,000 cpm) nts 853-1040, 1021-1219, 
and 1203-1372 were incubated with varying concentrations of CRDBP as shown. 
Samples were electrophoresed in a 4% native polyacrylamide followed by 
autoradiography.
Since the 1021-1219 (199 nts) P-TrCPl RNA fragment bound best, it was further 
divided and in vitro transcribed into six smaller fragments by shortening the RNA at both 
the 5’ and 3' ends (Table 10 and Figure 28).
P-TrCPl p-TrCPl p-TrCPl p-TrCPl p-TrCPl p-TrCPl
1051-1219 1091-1219  1131-1219 1021-1190 1021-1150 1021-1110
1 2  } 4 5 6 7 8 9 10 11 12
Figure 28. In  vitro transcription of 32P-UTP labeled p-TrCPl RNA Fragments. PCR- 
amplified DNAs were used as templates for in vitro transcription to generate p-TrCPl 
RNA fragments nts 1051-1219, 1091-1219, 1131-1219, 1021-1190, 1021-1150 and 1021- 
1110 RNA samples were then electrophoresed in a 6% denaturing polyacrylamide gel 
followed by autoradiography.
All the six smaller fragments tested, 1051-1219 (169 nts), 1091-1219 (129 nts), 
1131-1219 (89 nts), 1021-1190 (170 nts), 1021-1150 (130 nts) and 1021-1110 (90 nts), 
were found to bind CRDBP with slightly varying degree of affinity (Figures 29, 30 and
p -TYCP1 853-1040 p -T rC P l 1021-1219 p -T rC P l 1203-1372
31).
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Figure 29. Electrophoretic Mobility Shift Assay of recombinant CRDBP with p- 
TrCPl RNA fragments. [32P] p-TrCPl RNAs (20,000 cpm) nts 1021-1219, 1051-1219, 
1091-1219 and 1131-1219 were incubated with varying concentrations of CRDBP as 
shown. Samples were electrophoresed in a 4% native polyacrylamide followed by 
autoradiography.
P -T rC P l 1021-1219 p -T rC P l 1021-1190 P -T rC P l 1021-1150 p -T rC P l 1021-1110
CRD-BP: <a> V
Bound £  H
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Figure 30. Electrophoretic Mobility Shift Assay of recombinant CRDBP with P- 
TrCPl RNA fragments. Autoradiograph of P-TrCPl RNA (20,000 cpm) incubated with
varying concentrations of CRDBP after electrophoresis at 25mA for 55mins in a 4% 
polyacrylamide gel exposed for 8 hours. [32P] P-TrCPl RNAs (20,000 cpm) nts 1021- 
1219, 1021 -1190, 1021 -1150 and 1021 -1110 were incubated with varying concentrations 
of CRDBP as shown. Samples were electrophoresed in a 4% native polyacrylamide 
followed by autoradiography.
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CRD-BP
Bindine
1021----------------- ------------------- - 1219 199nts ++++
1021----------------- ------------ 1190 170nts ++++
1021----------------- ----- 1150 130nts +++
1021----------------- 1110 90nts +
1051 --------------- -------------------- 1219 169nts ++++
1091------- ------------------ 12i9 129nts +++
1131 - ------------------ 1219 89nts ++
Figure 31. Summary of p-TrCPl RNA fragments and their relative binding affinity 
for CRDBP. The region of interest is shown in blue and the smaller fragments are shown 
in black. (++++), (+++), (++), and (+) Indicate ~90%, ~70%, ~40% and ~10% binding 
respectively.
Discussion
In general, the RNA mapping data of MITF, c-myc and P-TrCPl indicated that as 
the RNA region is decreased in size, so does the binding affinity. All the regions of 
MITF that retained binding affinity for CRDBP were 1550-1709,1550-1669, 1581-1740, 
and 1621-1740, and this outlined a smaller region of MITF 1621-1709 (89 nts) that could 
interact with CRDBP. All these regions, including the smaller 1621-1709 (89 nts) region, 
outline a binding site for miR-548c-3p spanning 1658-1680 (Figure 2D from Goswami et 
al) (30). This suggests that CRDBP could bind at this position, making it a potential 
point for the regulation of MITF RNA. Two miR-340 binding sites that flank the MITF 
1621-1709 region could also be interrupted when CRDBP binds in the MITF region of 
1621-1709.
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There was initial difficulty in the synthesis of MITF 1550-1740 in comparison to 
MITF 1330-1550 and other fragments due to the higher than usual number of repeated 
uracils (U’s) in a row. To compensate for this, the normal in vitro transcription reaction 
was spiked with four times the usual amount of cold UTP, from 10 pmol UTP to 40 pmol 
UTP.
The mapping of c-myc RNA fragments indicated all regions of c-myc RNA 
bound to CRDBP except for 1845-1886 (42 nts) and 1705-1744 (40 nts) (Figures 16 and 
17). The other two 40 nt regions of MITF, 1550-1589 and 1701-1740 also did not 
indicate any binding to CRDBP (Figure 9 and 11). Given that a 39 nt fragment of CD44 
RNA had been established to be bound by CRDBP, it is unlikely that the two 40 nt 
fragments of c-myc and MITF RNAs that did not bind was due to an artifact based on 
their reduced size (109). The MITF RNA fragment 1550-1619 (70 nts) clearly showed 
no binding activity, which also encompasses the smaller 40 nt fragment, supporting the 
notion that the two smaller 40 nt fragments of c-myc and MITF are in fact incapable of 
binding CRDBP. From this, I conclude that the smallest region of c-myc RNA bound by 
CRDBP is 1735-1792 (58 nts), which lies within previously the reported region of 1705- 
1792 (88 nts) and 1705-1886 (182 nts) CRD instability region of c-myc (56, 61). In the 
neighbouring region 1594-1614 of c-myc, miR-185-3p has shown to bind to c-myc and 
regulate c-myc protein level (110). Binding of CRDBP to the CRD region (1705-1886 
nts) could disrupt the ability of miR-185-3p to regulate c-myc RNA.
The smaller MAPK regions, which were transcribed all showed binding to 
CRDBP, suggesting that there may be multiple areas where CRDBP is able to bind with 
MAPK RNA.
59
The initial (3-TrCPl RNA region of 510-1372 (863 nts) that was split into five 
smaller fragments all exhibited binding affinity with CRDBP. Although they all 
indicated some affinity for CRDBP, fragment 1021-1219 (199 nts) had the greatest 
affinity for CRDBP.
From these mapping experiments, it is clear that there is some specificity for 
which RNA fragments can bind CRDBP. The mapping of these smaller regions of RNA 
could share similarities in sequence or structure. Being able to recognize these 
similarities could pave the way to the design of small molecules that mimic the RNA.
The understanding of the structures associated with the RNAs mapped here, as well as the 
K-Ras, GLI1 and MDR1 RNAs mapped by other members in the Lee lab, will be 
discussed in Chapter 4.
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Chapter 3- Analysis of CRDBP-RNA Interaction
Part A Characterizing the CRDBP-RNA interaction in vitro using Electrophoretic 
Mobility Shift Assay, in cells and in vivo
As described in Chapter 1, it is important to understand the function of CRDBP, 
notably in how it binds to its oncogenic target RNAs. Previous research using deletion 
studies of CRDBP orthologs have demonstrated that the KH domains are responsible for 
interacting with RNA (76,111). In addition, previous work on an RNA binding protein 
NusA, which interacts through KH domains have demonstrated clearly that mutation at 
the G-X-X-G motif to D-X-X-G, renders the KH domain inactive for binding with RNA 
molecules (112). The aim of this section of Chapter 3 was to identify which of the KH 
domain(s) of CRDBP play a key role in interacting with RNA in the context of the entire 
protein. To do so, site-directed mutagenesis was executed to generate and purify 
recombinant CRDBP single and double KH variants (Barnes et al submitted). The same 
mutations were also introduced on pcDNA3-FLAG-CRDBP plasmid to express the 
CRDBP variants in HeLa cells and to assess their ability to physically interact with 
specific mRNA species. These variants were also sub-cloned into pSp64TNE vectors for 
the expression of CRDBP in zerbrafish (Danio rerio) in an effort to assess their influence 
on the CRDBP-MITF RNA interaction and hence on pigmentation in vivo.
3.1 Methodology
3.1.1 Purification and Dialysis of WT-CRDBP and Variants
Purification of wild type and variant CRDBP proteins were performed in identical 
fashion as described in Chapter 2. The purified WT-CRDBP and variant proteins were 
dialyzed as described in Chapter 2. All the proteins were quantified using the BCA
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protein assay kit (Catalog # PI23225, Thermo Scientific).
3.1.2 Radiolabeling of RNA and Electrophoretic Mobility Shift Assay
(EMSA)
Radiolabeling of c-myc 1705-1886 (182 nts) and MITF 1550-1740 (191 nts) RNA 
fragments were performed as described in Chapter 2. The manner in which the 
radiolabeled RNA and dialyzed protein were assessed in EMSA is described in Chapter 
2 .
3.1.3 Quantification and Representation of EMSA
The autoradiographs of the EMSAs generated by the Cyclone Storage Phosphor 
Screen System and Optiquant software was used to determine the dissociation constant 
(IQ) of CRDBP with the [32P] c-myc CRD 1705-1886 and [32P] MITF 1550-1740 RNA 
substrates. Using the Optiquant Software, bound and unbound values were determined 
by calculating the total signal in each lane and measuring how much of that belonged to 
either bound or unbound states of the respective [32P] RNA substrate (Figure 1). The Hill 
equation was then used to calculate the IQ using these bound and unbound values 
(Appendix, Figures S3 to S5).
3.1.4 Immuno-precipitation of CRDBP Variants from HeLa cells
Immuno-precipitation was performed using monoclonal ANTI-FLAG® M2 
antibody (Sigma-Aldrich) to assess mRNA associated with the wild-type and variant 
CRDBP. Human cervical cancer cells, HeLa, purchased from American Tissue Culture 
Collection (ATCC) were cultured in Minimum Essential Media (Gibco) containing 10%
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Fetal Bovine Serum and plated on 100 mm dishes at 1 x 105 cells/mL. After one day of 
growth on the 100 mm dishes, transfection was performed using Lipofectamine 2000 
reagent (Invitrogen), Opti-MEM® (Gibco) and pcDNA3-FLAG plasmid containing, 
empty vector, wild-type and variant CRDBP. Two days of growth after transfection, the 
cells were lysed using TCLB-L buffer [TCLB (50 mM Tris, 130 mM NaCl, 625 uM 
EDTA, 2.5% Triton x-100), 7 x TCLB-C (TCLB, complete tablet), VRC (800 pM), DTT 
(400 pM), RNasin (40 U/ pL)]. The cells were incubated on ice for 5 minutes after 
addition of the TCLB-L buffer. The cells were transferred to an eppendorf tube on ice, 
after the use of a cell scrapper to remove the cells from the plates. The lysed cells were 
then aspirated using a 26 gauge needle 5 times to break up the nuclei before incubation 
on ice for an additional 30 minutes.
During the 30-minute incubation on ice, Protein-G agarose beads used for the 
immuno-precipitation were equilibrated. First the beads are resuspended until 
homogenous, and 150 pL of the homogenized beads were aliquot into Eppendorf tubes 
for each plate of cells. The beads were then centrifuged for 1 minute at 3000 x g, and the 
supernatant was removed. The beads were then resuspended in 500 pL of TCLB-L 
buffer, centrifuged for 1 minute at 3000 x g, and the supernatant removed. This TCLB-L 
wash step was repeated once more and then the Protein-G agarose beads were 
resuspended in 75 pL of TCLB-L buffer.
After the 30-minute incubation on ice, the lysed cells were centrifuged for 10 
minutes at 16,100 x g at 4°C. The supernatant was collected in a new eppendorf in order 
to pre-clear the cell lysate. The cell lysate was pre-cleared by the addition o f 50 pL of the 
equilibrated Protein-G agarose beads and incubating on a shaker for a minimum of 1 hour
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at 4°C before centrifuging the lysate and bead mixture at 3000 x g for 1 minute at 4°C. 
Pre-clearing was performed one more time, for a total time of 3 hours of incubation. The 
pre-cleared cell lysate was then incubated with 5 pL o f the monoclonal ANTI-FLAG®
M2 antibody (Sigma-Aldrich) on shaker overnight at 4°C.
The next morning, the remaining equilibrated Protein-G agarose beads were 
added to the pre-cleared lysate and antibody mixture, and incubated on a shaker for four 
hours at 4°C. After the incubation, the lysate and bead mixture was centrifuged at 3000 x 
g for 1 minute at 4°C. The supernatant was removed, and the beads were washed four 
times with TCLB-W buffer [TCLB, DTT (400 uM), VRC (800 uM)] for 5 minute at 4°C 
each. Next the beads were washed five times with TCLB-U [TCLB, DTT (800 uM),
VRC (1.60 mM), 0.46 M Urea] for 15 minutes at 4°C each. After each wash the bead 
and wash mixture was centrifuged at 3000 x g for 1 minute at 4°C. After resuspension of 
the beads on the forth wash of the TCLB-U wash step, half of the resin was removed, 
centrifuged at 3000 x g for 1 minute, and re-suspended in 16 uL of H2O and stored at - 
80°C to be used for Western blot analysis. The remaining beads were washed for a fifth 
time, supernatant removed, and incubated with 100 uL of TCLB-PK [500 uL TCLB-W, 
Proteinase K (150 ug), 0.1 % SDS] for 30 minutes at 50°C. Phenol/chloroform extraction 
was performed twice to extract the RNA, which was then precipitated at -80°C with the 
addition of 4 uL yeast tRNA (5 mg/ml), 24 uL 3 M sodium acetate and 500 uL 100% 
ethanol in a new eppendorf tube. The precipitated RNA was then resuspended in 8 uL of 
nuclease-free H2O and DNase treated using a DNA-free kit (Ambion). The resuspended 
8 uL RNA had 1 uL of 10X buffer and 1 uL of DNase 1 added and incubated at 37°C for 
30 minutes as instructed by the Ambion DNase treatment kit. Next, 2 uL of the
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inactivating reagent was added to the mixture and incubated at room temperature for 2 
minutes, and then centrifuged at 10,000 x g for 1.5 minutes. The purified RNA was then 
used as template to produce cDNA for real-time quantitative polymerase chain reaction 
(RT-qPCR) analysis.
3.1.5 RT-qPCR of RNA Associated with FLAG-CRDBP Variants 
The BioRad iScript™ cDNA Synthesis Kit was used for cDNA synthesis. 
Equivalent amount of RNA were used for each cDNA synthesis reaction. Each reaction 
consisted of RNA (~1 ug), 4 uL of 5 x iScript mix, 1 uL of reverse transcriptase and H2O 
(up to 20 uL) which was placed in the thermocyler and the first strand synthesis of cDNA 
was done using the following program: 25°C 5 minutes, 42°C 30 minutes, 85°C 5 
minutes. The qPCR reaction mixtures (25 uL) then consisted of 2 uL cDNA, 12.5 uL 
iQ™ SYBR® Green Supermix (Bio-Rad), 1.0 uL forward primer (10 uM), 1.0 uL reverse 
primer (10 uM) and 9.5 uL nuclease-free water and were added to 96-well PCR plates 
(Axygen). The 96-well plates were placed in a BioRad iQ5 cycler, where the cDNA was 
amplified in a two-step PCR reaction. Optimal temperature for each primer set used (P- 
actin, c-myc and CD44 Table 1) were previously described in Dr. Lee’s lab, using melt- 
curve analysis, prior to all qPCR experiments (109). The efficiency of the qPCR 
reactions were established using the standard curve method.
Table 11. Primer sets used in real-time RT-PCR experiments.
Forward, 5'-ACGAAACTTTGCCCATAGCA-3'
C"myC Reverse, 5'-GCAAGGAGAGCCTTTCAGAG-3'
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3.1.6 D. rerio studies
3.1.6.1 Preparation of pSp64TNE-Plasmid
In order to in vitro transcribe capped mouse WT-CRDBP and CRDBP variant 
RNAs for injection into Danio rerio, the genes encoding the mouse WT-CRDBP and 
CRDBP variants needed to be first sub-cloned from pcDNA3 vector into pSp64TNE 
vector. This required gene amplification with the introduction of restriction sites to allow 
for ligation into pSp64TNE vector. Polymerase chain reaction was performed using 100 
ng of pcDNA3 CRDBP gene of interest, 5X Phusion DNA polymerase buffer, 0.28 mM 
dNTPs, 2 Units of Phusion DNA Polymerase and 0.5 pM primers (Table 2). The 
reactions were then placed in a thermocycler using the following program -  98 °C for 30 
seconds, then 98°C-15 seconds, 55°C-30 seconds, 72°C-2 minutes for 25 cycles followed 
by incubation at 72°C for 10 minutes. The PCR product was analyzed on a 2% agarose 
gel followed by gel extraction using QIAEX® II Gel Extraction Kit. The gel extracted 
insert and pSp64TNE plasmid were double digested using -500 ng of DNA, 10 Units of 
Kpnl, 20 Units of EcoRI-HF, NEBuffer 2.1 and heated to 37°C for 2 hours. The digested 
vector and inserts were then analyzed on 2% agarose gel, and gel extracted using 
QIAEX® II Gel Extraction Kit. Next two ligation reactions were prepared using digested 
pSp64TNE and digested inert in a 1:1 and 2:1 (pSp64TNE:Insert) together with 10X 
ligation buffer, and 400 Units of Ligase. A control was prepared with 10X ligation 
buffer, 40 Units of Ligase and digested pSp64TNE. All ligation reactions were left at 
room temperature for 2 hours. Competent DH5a E. coli cells were thawed from -80°C on 
ice, added to the ligation reactions and incubated on ice for 30 minutes. The DH5a E. 
coli cells were then heat shocked at 42°C for 90 seconds, placed on ice for 2 minutes, 500
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(xL of LB broth added and then incubated at 37°C for 1 hour. The transformed DH5a E. 
coli cells were then transferred onto LB-Ampicillin agar plates and incubated overnight at 
37°C. Colonies from both the 1:1 and 2:1 (pSp64TNE:Insert) were compared to the 
control (vector only ligation) and cultured in 3mL LB-Ampicillin broth overnight at 
37°C. Liquid colony PCR was performed on the overnight cultures with 10X 
ThermoPol™ Reaction buffer, 0.28 mM dNTPs, 5 Units of DNA Taq Polymerase and 0.5 
pM primers (Table 1). The liquid colony PCR reactions were then placed in a 
thermocycler using the following program -  95 °C for 2 minutes, then 95°C-15 seconds, 
55°C-15 seconds, 72°C-1 minute for 25 cycles followed by incubation at 72°C for 2 
minutes. The PCR product was analyzed on a 1% agarose gel. DNA Mini-prep 
(QIAgen) was performed on colonies with appropriate size bands visible on the 1% 
agarose gel and then sent for DNA sequencing for verification. A total of five 
pSp64TNE sub-clones were generated: WT-CRDBP, CRDBP-KH1, CRDBP-KH4, 
CRDBP-KH1 -2 and CRDBP-KH3-4.
Table 12. Primers used in the gene amplification of WT-CRDBP and Variants._____
Primer SequencePrimer
5' ACCA GAATTC TAC CTT CCT CCG AGC CTG 3CRDBP EcoRI
Reverse___________Handle EcoRI Site Reverse Complement of CRDBP Stop
3.1.7 Circular Dichroism Conditions and Settings
All samples were scanned in triplicate from 200 to 320 nm at a rate of 20 nm/min 
using the Jasco J-815 Circular Dichroism Spectrometer. The raw scanned data were 
transferred from the Jasco Spectral Manager software into an excel spreadsheet and
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converted from mdeg to molar ellipticity per residue as shown Figure 32. The samples 
analyzed by circular dichroism (Table 13) were either diluted in nuclease-free water or 
dialysis buffer as described in Table 2. All samples were blanked with a matching 
reference sample containing either nuclease-free water or dialysis.
32,980 x C x L x N
0 = Raw circular dichroism amplitude in mdeg 
C = Sample concentration in mol/L 
L = Cell path length in cm 
N -  Number of residues in the molecule
Figure 32. The equation for calculating molar ellipticity per residue from measured 
mdeg.
Table 13. RNA Molecules analyzed by Circular Dichroism.
Molecular Weight Number of Residues
MITF 1621-1709
3.2 Results
Part A: Characterizing the CRDBP-RNA interaction in vitro, in cells, and in vivo 
Part I: In Vitro
3.2.1 EMSAs with c-myc RNA and CRDBP Variants
The binding profile of CRDBP KH variants on c-myc RNA was assessed using 
EMSA. As shown in Figure 33B, both CRDBP-KH3 and CRDBP-KH4 showed 
comparable binding to [32P] c-myc RNA 1705-1886 (182 nts) as the WT-CRDBP. In 
contrast, single KH mutation variants CRDBP-KH1 and CRDBP-KH2 showed a 
reduction in binding as compared to the WT-CRDBP (Figure 33A).
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Figure 33. Electrophoretic mobility shift assay of the recombinant wild-type CRDBP 
and CRDBP variants. [32P] c-myc 1705-1886 (182 nts) RNA substrate (20,000 
cpm/reaction) was incubated with varying concentrations of CRDBP variants as shown. 
Samples were electrophoresed in a 4% native PAGE gel followed by autoradiography. 
Data shown are representatives from at least four experiments using proteins from at least 
two separate preparations.
To obtain quantitative measurements on the affinity of CRDBP for the [32P] c- 
myc RNA 1705-1886 (182 nts), the dissociation constant (K<i) was determined using the 
Hill equation. The binding data for each of the CRDBP variants (Figure 33A and 33B) 
showed a sigmoidal curve when plotted and were thus fit using the Hill equation (Figure 
34A-D).
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Figure 34. CRDBP variants binding curves as generated by the Hill Equation.
Binding curves were generated using densitometry and the data from Figure 3A-B with at 
least two biological replicates as well as three separate experiments were pooled. CRDBP 
variants were incubated with [32P] c-myc RNA 1705-1886 (182 nts) and the binding 
profiles were analyzed using densitometry. Percent bound vs Percent unbound values 
were used to generate the binding curves and calculate the dissociation constant. Errors 
bars indicate the standard error mean for A-D.
Each of the following dissociation constants were determined with [32P] c-myc 
RNA 1705-1886 (182 nts) as the substrate and the use of densitometry to fit into the Hill 
equation. The dissociation constant for WT-CRDBP was determined to be 398 ± 52 nM
70
(Figure 33A). The dissociation constant for CRDBP-KH1 was determined to be 723 ± 75 
nM (Figure 33A). The dissociation constant for CRDBP-KH2 was determined to be 360 
± 70 nM (Figure 33A). The dissociation constant for CRDBP-KH3 was determined to be 
320 ± 42 nM (Figure 33B). The dissociation constant for CRDBP-KH4 was determined 
to be 320 ± 59 nM (Figure 33B). The measured dissociation constants are summarized in 
Table 14.
3.2.2 EMSA with MITF RNA and CRDBP Variants
Figure 35 shows representative results from EMSA experiments in assessing the 
WT CRDBP and its KH variants for ability to bind to MITF RNA. CRDBP-Y5A and 
CRDBP-D526E showed comparable binding to [32P] MITF RNA 1550-1740 (191 nts) as 
the WT-CRDBP (Figure 35A). CRDBP-Y5A and CRDBP-D526E variants are negative 
controls and were expected to have no effect on binding affinity and similar binding 
profiles as the wild type CRDBP. The Y5A mutation is located in RRM1 of CRDBP and 
D526E is located within the variable loop of KH4 between 02 03- Both Y5A and D526E 
are negative controls because those two regions are not involved in the interaction with 
RNA. From the single mutant variants, CRDBP-KH1 showed a reduced binding affinity 
to [32P] MITF RNA 1550-1740 (191 nts) as compared to the WT-CRDBP (Figure 35A- 
B). The other single KH variants, CRDBP-KH2, CRDBP-KH3, CRDBP-KH4 exhibited 
even more reduced binding with [32P] MITF 1550-1740 (191 nts) in comparison to the 
WT-CRDBP (Figure 35A-C). Except for CRDBP-KH3-4, all CRDBP variants with 
double point mutations (CRDBP-KH1-2, KH1-3, KH1-4, KH2-3, KH2-4) showed 
complete abrogation of binding with [32P] MITF RNA 1550-1740 (191 nts) (Figure 35A, 
35D-H).
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Figure 35. Electrophoretic mobility shift assay of recombinant wild-type and mutant
CRDBP. [32P] MITF RNA 1550-1740 (191 nts) RNA substrate (20,000 cpm/reaction) 
was incubated with varying concentrations of CRDBP variants as shown. Samples were 
electrophoresed in a 4% native PAGE gel followed by autoradiography. Data shown are 
representatives from at least three experiments using at least two separately prepared 
recombinant proteins.
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From the EMSAs of [32P] MITF RNA 1550-1740 (191 nts) with WT-CRDBP, 
CRDBP-Y5A, CRDBP-D526E and CRDBP-KH3-4 densitometry was performed to 
quantify the binding profiles. For CRDBP-KH2, KH3, KH4, KH1-2, KH1-3, KH1-4, 
KH2-3 and KH2-4 densitometry was not measured as these variants exhibited little to no
binding affinity with MITF 1550-1740 (191 nts) (Figure 35B-C). The binding data was 
then fit into the Hill equation and showed a sigmoidal curve when plotted (Figure 36).
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Figure 36. CRDBP variants binding curves as generated by the Hill Equation.
Binding curves were generated using densitometry from Figure 35A-H. The data were 
pooled from at least two biological replicates as well as four separate experiments.
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CRDBP variants were incubated with [32P] MITF RNA 1550-1740 (191 nts) and the 
binding profiles were analyzed using densitometry. Percent bound vs Percent unbound 
values were used to generate the binding curves and calculate the dissociation constant.
Each of the following dissociation constants were determined with [32P] MITF 
RNA 1550-1740 (191 nts) as the substrate and the use of densitometry fit into the Hill 
equation. The dissociation constant for WT-CRDBP was determined to be 131 ± 3 nM 
(Figure 35A, Table 14). The dissociation constant for CRDBP-Y5A was determined to 
be 86 ± 2 nM (Figure 35A, Table 14). The dissociation constant for CRDBP-D526E was 
determined to be 91 ± 6 nM (Figure 35A). The dissociation constant for CRDBP-KH3-4 
was determined to be 155 ± 19 nM (Figure 35H).
The summary of IQ values for each of the CRDBP variants that bind with c-myc 
1705-1886 (182 nts) and MITF 1550-1740 (191 nts) are shown in Table 14. Statistical 
analysis was performed using student t-test model.
Table 14. Summary table of the different CRDBP variants and determined IQ 
values.
Protein c-myc 1705-1886 (182nts) MITF 1550-1740 (191nts)
468 ± 46 nM 85 ± 2 nM
723 ± 75 nM
321 ± 4 3 n M No Bindin
KH1-2 No Bindin No Bindin
No BindinKH1-4 No Bindin
No Bindin No BindinKH2-4
Student’s t-test (n=4, P < 0.05) was used to determine whether there was a statistically 
significant difference between the IQ values of the KH single mutants as compared to the 
WT-CRDBP IQ. The asterisk indicates that the p-value is less than 0.05. The initials MB 
indicate Mr, Mark Barnes completed the EMSAs and Kd values (109).
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Part II: In cells
To determine if mutation in KH domains has any effect on the ability of CRDBP 
to physically associate with its target mRNA in cells, pcDNA-FLAG-CRDBP plasmids 
were expressed in HeLa cells. Immuno-precipitation (IP) using anti-FLAG antibody was 
then performed. IP was followed by western blot analysis to ensure equivalent protein 
expression, confirming difference in bound RNA levels between wild-type and variants 
are due to differences in the ability of those immuno-precipitated CRDBP variants to bind 
with RNAs. As shown in Figure 37A, equal amount of FLAG-CRDBP were present in 
the cell lysates of all samples. RT-qPCR was then performed on the isolated RNA for 
measurements of c-myc, CD44 and P-actin mRNA. The measured mRNA levels of c- 
myc and CD44 for all variants containing a double mutation were found to be reduced in 
comparison to the wild-type CRDBP as shown in Figure 37B and 37C. For P-actin 
mRNA levels, the relative amounts between FLAG-WT-CRDBP and the variants did not 
change as shown in Figure 37D.
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Figure 37. Analysis of specific mRNAs physically associated with the WT CRDBP 
and its variants. pcDNA-FLAG-CRDBP plasmids were transfected into HeLa cells as 
described in the Methodology section. FLAG-CRDBP-RNA complexes in cell lysates 
were immune-precipitated with anti-FLAG antibody. (A) Immuno-precipitated lysate was 
used in Western blot analysis to detect and confirm comparable exogenous FLAG- 
CRDBP protein expression using anti-FLAG antibody. (B-D) (3-actin, CD44 and c-myc 
mRNAs isolated from the complexes were measured using qRT-PCR. mRNA levels were 
expressed over the pcDNA-FLAG control and compared to WT-CRDBP. Statistical 
significance between the expression of target genes in WT-CRDBP and CRDBP variants- 
transfected cells was assessed by the unpaired Student’s t-test (n=4). The asterisk 
indicates that the p-value is less than 0.05.
Part III: In vivo
A previous study (Goswami et al 2010) showed that upon injection of zebrafish 
embryos with a specific morpholino against zebrafish CRDBP, suppression o f mifta 
(zebrafish’s MITF) mRNA level was observed which was followed by reduction in
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pigmentation in zebrafish 48 hours after fertilization (30). This study prompted us to 
investigate the role of KH domains of CRDBP in manifesting an in vivo phenotype, 
which in this case would be cell pigmentation in zebrafish. In collaboration with Dr. 
Andrew Miller’s lab in the Hong Kong University of Science and Technology, Dr. Lee 
first needed to determine whether the mouse WT CRDBP can in fact rescue the 
pigmentation in zebrafish which had been previously knocked down with the specific 
morpholino against zebrafish CRDBP. Unfortunately, the experimental plan turned out 
to be more complicated than previously anticipated. Firstly, Dr. Lee discovered a 
significant mistake was made by the previous study. The morpholino used in the 
previous study was in fact targeting IGFBP1 (Insulin-like growth factor-binding protein 
1) mRNA, and not IGF2BP1 (CRDBP) mRNA. Dr. Lee later designed a new 
morpholino, which is specific for IGF2BP1 (CRDBP) and performed the planned 
zebrafish experiments. Injections of four concentrations of CRDBP-morpholinos (4, 8,
12 and 16 ng) into at least three zebrafish embryos did not result in any observable 
changes in phenotype, including pigmentation. The experiments were repeated two more 
times using zebrafish eggs produced from different zebrafish. But again, no changes in 
phenotype, including pigmentation, were observed. Also surprisingly, when Dr. Lee used 
the wrong morpholino previously used by Goswami et al, no reduction in pigmentation 
was observed in zebrafish (30).
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Part B: Analysis of RNA Species using Circular Dichroism Spectroscopy
3.2.7 Analysis of RNA Species using Circular Dichroism Spectroscopy
Circular dichroism (CD) spectroscopy has been successfully used to assess 
secondary structure changes in nucleic acids (DNA and RNA) upon interaction with 
proteins (113, 114). Here, I explore the possibility of using the CD spectroscopy to 
measure secondary structural changes in RNA upon interaction with CRDBP.
For the circular dichroism spectroscopy, optimal RNA concentration had to be 
first established. Kras 240-332 (93 nts) RNA was scanned at four concentrations, 435 
nM, 869 nM, 1738 nM and 3314 nM in nuclease-free water (Figure 38A-D). As the 
concentration of the Kras 240-332 (93 nts) RNA molecule increased, the quality of the 
spectra was found to increase (Figure 38A-D). At the maximum concentration of 3314 
nM of Kras 240-332 (93 nts) RNA molecule used, the spectra was at the best quality. 
However, regardless of the concentrations of Kras RNA used, a maximal peak was 
observed at around 265 nm. This ~3000 nM concentration range is where further RNA 
spectral analyses were conducted.
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Figure 38. Circular Dichroism Spectra of Kras 240-332 (93 nts) RNA at different 
concentrations. (A) Kras 240-332 (93 nts) at 435nM. (B) Kras 240-332 (93 nts) at 
869nM. (C) Kras 240-332 (93 nts) at 1738nM. (D) Kras 240-332 (93 nts) at 3314nM. 
Kras RNA was resuspended in nuclease-free water.
Next, in addition to Kras 240-332 (93 nts), c-myc 1705-1792 (88 nts), MITF 
1621-1709 (89 nts) and Kras 148-239 (92 nts) were also scanned using the circular 
dichroism spectrophotometer in nuclease-free water (Figure 39). The Kras 148-239 (92 
nts) RNA molecule does not bind with CRDBP, whereas the Kras 240-332 (93 nts) RNA 
molecule does (Mackedenski S, unpublished observation). The data from all four of 
these RNA molecules were then plotted onto a single graph in order to determine possible 
differences between them (Figure 39). Other than the slight differences in the height of 
the peak close to 263nm, the CD spectra of all the four RNAs look remarkably similar 
with a single peak (Figure 39).
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Figure 39. Circular Dichroism Spectra of different RNA molecules in water. The c-
myc 1705-1792 (88 nts) RNA at 3514 nM is in blue. The MITF 1621-1709 (89 nts) RNA 
at 3491 nM is in purple. The Kras 240-332 (93 nts) RNA at 3337 nM is in green. The 
Kras 148-239 (92 nts) RNA at 3314 nM is in orange.
The same four RNA molecules were also scanned in dialysis buffer, in order to 
see if the buffer conditions change the spectra of measured RNA (Figure 40). This is 
important because subsequent experiments in assessing CRDBP-RNA interactions will 
utilize dialysis buffer. When the data from all four RNA molecules were compared on 
one graph, they produced a single peak with varying intensities (Figure 40), which were 
similar to what was previously observed when the RNAs were resuspended in water
(Figure 39).
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Figure 40. Circular Dichroism Spectra of different RNA molecules in dialysis buffer.
The c-myc 1705-1792 (88 nts) RNA at 3514 nM is in blue. The MITF 1621-1709 (89 nts) 
at 3491 nM is in purple. The Kras 240-332 (93 nts) RNA at 3337 nM is in green. The 
Kras 148-239 (92 nts) RNA at 3314 nM is in orange.
When the CD spectra of the four RNA molecules in nuclease-free water (Figure
39) are plotted on the same graph as the four RNA molecules in dialysis buffer (Figure
40) as shown in Figures 41A-D the single peaks are similar in shape and intensity. The 
solid colour line represents the CD spectra from the RNA molecule in nuclease-free water 
and the black dotted line represents the CD spectra of the RNA molecule in dialysis 
buffer (Figures 41 A-D).
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Figure 41. Comparison between water and dialysis buffer on the Circular Dichroism 
Spectra of different RNA molecules. The solid colour line represents the sample diluted 
in water and the dotted black line represents the sample diluted in dialysis buffer. (A) c- 
myc 1705-1792 (88 nts) at 3514 nM. (B) MITF 1621-1709 (89 nts) at 3491nM. (C) Kras 
240-332 (93 nts) at 3337nM. (D) Kras 148-239 (92 nts) at 3314 nM.
Next, the CD spectra of RNAs were then determined in the presence of CRDBP 
(Figures 42A-C, 43A-C and 44A-C). Kras 148-239 (92 nts) 1807 nM RNA molecule 
was scanned in dialysis buffer in the presence or absence of 1807 nM CRDBP as shown 
in Figures 42A and 42B respectively. These two scans were then plotted onto the same 
graph, where the solid colour line represents the Kras 148-239 (92nts) 1807 nM RNA 
molecule with 1807 nM CRDBP sample, and the black dotted line represents the Kras 
148-239 (92nts) 1807 nM RNA alone (Figure 42C). Both the Kras 148-239 (92nts) with 
or without 1807 nM CRDBP present generated almost identical single peak spectra as 
shown in Figure 42C.
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Figure 42. Circular Dichroism Spectra of Kras 148-239 (92 nts) RNA in the presence 
of WT-CRDBP. (A) Kras 148-239 (92 nts) 1807 nM RNA in dialysis buffer. (B) Kras 
148-239 (92 nts) 1807 nM RNA in the presence of WT-CRDBP 1807 nM. (C) Overlay 
of CD Spectra A and B.
Kras 240-332 (93 nts) 1824 nM in the presence of 1824 nM of CRDBP in dialysis 
buffer was also scanned (Figure 43A) and compared to Kras 148-239 (92 nts) in the 
presence o f 1807 nM CRDBP (43B) by plotting them onto the same graph as shown in 
Figure 43C. The two CD spectra scans of two different Kras RNA molecules in solution 
with CRDBP showed a single peak with similar intensities (Figure 43C). The solid 
colour line represents Kras 240-332 (93 nts) 1824 nM RNA molecule with 1824 nM 
CRDBP and the black dotted line represents Kras 148-239 (92 nts) 1807 nM molecule 
with 1807 nM CRDBP (Figure 43).
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Figure 43. Circular Dichroism Spectra of different Kras RNA molecules in the 
presence of WT-CRDBP. (A) Kras 240-332 (93nts) 1824nM RNA in the presence of 
WT-CRDBP 1824nM. (B) Kras 148-239 (92nts) 1807nM RNA in the presence of WT- 
CRDBP 1807nM. (C) Overlay of CD Spectra A and B.
Reducing the KrasrCRDBP ratio was also conducted to determine if changes in 
RNA spectra can be observed. The Kras 240-332 (93 nts) 912 nM RNA molecule with 
1824 nM CRDBP was scanned (Figure 44B) and compared to Kras 240-332 (93 nts) 
1824 nM RNA molecule with 1824 nM CRDBP (Figure 44A). The results were then 
plotted onto the same graph as shown in Figure 44C. As shown, reducing the RNA 
concentration of Kras 240-332 (93nts) in half resulted in a single peak with similar 
intensity (Figure 44C). A higher RNA concentration will give rise to higher peak 
intensity at 263 nm, but when comparing RNA of similar concentrations, small changes 
in the peak intensity would be attributed to how RNA molecules absorb the light 
differently.
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Figure 44. Circular Dichroism Spectra of Kras 240-332 (93nts) RNA at different 
concentrations in the presence of WT-CRDBP. (A) Kras 240-332 (93nts) 1824nM 
RNA in the presence of WT-CRDBP 1824nM. (B) Kras 240-332 (93nts) 912nM RNA in 
the presence of WT-CRDBP 1824nM. (C) Overlay of CD Spectra A and B.
DISCUSSION 
Part A:
In  vitro
The reason for assessing the different RNA-binding abilities of CRDBP KH 
variants was to determine which KH domains play an important role in interacting with c- 
myc 1705-1886 (182 nts) and MITF 1550-1740 (191 nts) RNAs. One concern was 
whether the point mutations would affect the global structure of the protein, which is not 
the case as circular dichroism of WT-CRDBP and all the variants indicated similar, if not 
identical, CD spectra (115).
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The CRDBP control variants, Y5A and D526E, showed similar binding affinity as 
the WT-CRDBP for c-myc 1705-1886 (182 nts) RNA fragment (Table 14). In contrast, 
KH1 variant exhibited a significant reduction in RNA-binding ability suggesting that the 
KH1 domain plays an important role in interacting with c-myc 1705-1886 (182 nts) RNA 
fragment (Table 14, Figure 33A). The importance of the KH1 interaction with c-myc 
1705-1886 (182 nts) RNA fragment is exemplified with the fact that the CRDBP variants 
with mutations at KH1-2, KH1-3, and KH1-4 showed little to no binding (Table 14). It is 
also interesting, because KH2-3, and KH2-4 showed no binding with c-myc 1705-1886 
(182 nts) RNA fragment, and although the KH1 was unaffected, mutations in the other 
KH domains had an effect (Table 14). The CRDBP-KH3 and KH4 variants, as well as 
CRDBP-KH3-4 variant showed similar binding affinity as the WT-CRDBP, indicating 
that the G-X-X-G motif in these two KH domains are less important in interacting with c- 
myc 1705-1886 (182 nts) RNA fragment (Table 14). This also demonstrates that a 
single KH domain is not responsible for interacting with c-myc 1705-1886 (182 nts)
RNA fragment alone, but at least two.
For MITF 1550-1740 (191 nts) RNA fragment, both CRDBP control variants, 
Y5A and D526E, as well as KH3-4 variant showed binding affinity similar to that of the 
WT-CRDBP (Table 14, Figure 35A, 35H). The CRDBP KH2, KH3, KH4, KH1-2, KH1- 
3, KH2-3, and KH2-4 variants all showed no binding affinity with MITF 1550-1740 (191 
nts) RNA fragment (Table 14, Figure 35B-G). In comparison, the CRDBP-KH1 variant 
maintained some binding affinity with MITF 1550-1740 (191 nts) although the 
dissociation constant cannot be determined for comparison (Figure 35B, Table 14). 
Surprisingly the CRDBP-KH3-4 variant showed wild-type like binding affinity for MITF
87
1550-1740 (191 nts) RNA fragment although single variants CRDBP-KH3 and KH4 did 
not show binding as seen in Figures 35C and 35H (Table 14). This suggests that regions 
other than the G-X-X-G motif in KH3 and KH4 domains may have the capacity to 
cooperate in facilitating RNA interaction. From the single and double CRDBP variant 
work, the mutation at KH2 showed to have the greatest impact on CRDBP’s ability to 
bind with MITF 1550-1740 (191 nts) RNA fragment, as the mutation at KH1, showed to 
retain some binding and the double mutation at KH3-4 also retained some binding (Table 
14, Figure 35B and 35H).
In comparing the c-myc 1705-1886 (182 nts) with the MITF 1550-1740 (191 nts), 
the CRDBP-KH1 variant had a greater impact on the c-myc 1705-1886 (182 nts) RNA 
fragment ability to bind whereas the CRDBP-KH2 impacted MITF 1550-1740 (191 nts) 
RNA fragment to bind. The CRDBP-KH3-4 variant showed the retention of binding 
ability for both c-myc 1705-1886 (182 nt) RNA fragment and MITF 1550-1750 (191 nts) 
RNA fragment (Table 14). It then appears that the G-X-X-G motif in the KH1 and KH2 
domains play a greater role in interacting with these two RNA molecules than the G-X- 
X-G motifs in the KH3 and KH4 domains (Table 14).
In cells
The role of the G-X-X-G motif in the KH domains of CRDBP for binding 
mRNAs was further investigated in HeLa cells. This work initially began by a previous 
member in Dr. Lee’s lab in assessing the CRDBP single KH variants. It was found that 
KH1, KH2, KH3 had reduced affinity to c-myc RNA, and KH4 was comparable to the 
WT-CRDBP (115). The assessment of the CRDBP variants with double KH mutations,
8 8
however, showed a decrease in affinity to c-myc and CD44 RNAs, which correlated with 
the EMSAs of c-myc 1705-1886 (182 nts) and CD44 2862-3055 (194 nts) (Figure 37B-C, 
Table 14) (115). By comparing the cell data to the in vitro data, a clear correlation can be 
made that the mutations in the KH domains affected CRDBP’s RNA binding ability. The 
mutations at the G-X-X-G motifs in KH domains appeared to be enhanced in the cells as 
compared to in vitro. This is because the CRDBP-KH3-4 variant showed no binding to c- 
myc and CD44 mRNA from the IP experiments as compared to in vitro analysis where 
the CRDBP-KH3-4 variant demonstrated RNA binding (Figure 37B-C) (115).
In  vivo
The investigation into the role of KH domains of CRDBP in conferring in vivo 
phenotype, namely pigmentation in zebrafish, could not be performed. This is because 
Dr. Lee could not reproduce the results reported in the previous study (Goswami et al) 
using their incorrect morpholino (30). In addition, using a new and specific morpholino 
against CRDBP in zebrafish embyros, Dr. Lee could not observe any changes in 
phenotype, including pigmentation, in zebrafish.
Part B: Analysis of RNA species using Circular Dichroism spectroscopy
The optimal concentration for scanning RNA appears to be -3000 nM. At -900 
nM and -1500 nM concentrations, the quality of CD spectra generated appeared 
acceptable, but not as good as the spectra generated when -3000 nM RNA was used 
(Figure 38B-D). However, at -400 nM concentration of RNA, the CD spectra generated 
were less reproducible and tend to exhibit dimples in the line (Figure 38A). Between c-
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myc 1705-1792 (88 nts), MITF 1621-1709 (89 nts), Kras 240-332 (93 nts) and Kras 148- 
239 (92 nts) RNA molecules, there appears to be only minor differences in peak intensity 
(Figures 39A-E and 40A-E). Comparing these four RNA molecules in nuclease-free 
water versus dialysis buffer, again showed only minor differences in peak intensities 
(Figures 41A-D).
The spectra of Kras 148-239 (92 nts) RNA molecule did not alter much in the 
presence o f equivalent WT-CRDBP protein (Figures 42A-C). At first glance, this is not 
surprising because Kras 148-239 (92 nts) does not interact with WT-CRDBP in EMSA 
(Mackedenski S, unpublished data). However, what is surprising is the comparison of 
Kras 148-239 (92 nts) with WT-CRDBP to Kras 240-332 (93 nts) with WT-CRDBP 
(Figure 43A) as there was still no change in the generated RNA spectra (Figure 43C), 
because Kras 240-332 (93 nts) does in fact interacted with WT-CRDBP in EMSA assays 
(Mackedenski S, unpublished data). One would imagine that the RNA structure o f 
CRDBP-RNA binder would change shape upon interaction with CRDBP and in return 
have an altered CD spectra. Having compared Kras 148-239 (92 nts) and Kras 240-332 
(93 nts) RNA molecules in a 1:1 ratio with WT-CRDBP, which showed no change in CD 
spectra, a 2:1 Kras 240-332 (93 nts) RNA molecule:WT-CRDBP ratio was also scanned 
(Figure 44B). Such 2:1, Kras RNA:WT-CRDBP protein ratio was compared to the 1:1 
ratio, and still there was no evident of spectral changes (Figure 44C).
From all of these CD spectra scans of different RNA molecules, in the presence or 
absence of CRDBP, a very similar spectral pattern appears, namely the presence of a 
single peak at 263nm. This single peak at 263nm represents the absorbance o f RNA, and 
does not provide any detailed structural information of the individual RNAs or how these
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RNAs structure has changed in the presence of CRDBP. This being said, perhaps the 
global RNA structure does not change and hence no changes in CD spectra can be 
observed. It is possible that the CRDBP-RNA interaction only involves a number of 
critical nucleotides present in the single-stranded loop RNA regions and such interactions 
cannot be measured using CD spectroscopy.
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Chapter 4. Using in silico analytical methods to compare and contrast RNAs that 
bind CRDBP
Trying to understand the RNA is equally as important as the protein, in the 
context o f how a protein-RNA interaction is formed. Various labs have attempted to 
decode how an RNA’s structure plays a role in being recognized by the corresponding 
RBP, but most only report on the primary structure, neglecting the secondary and tertiary 
possibilities. For RBPs in the VICKZ family, this was first described in 1997 by Robert 
Singer’s group studying ZBP-1 which concluded that a 5’-ACACCC-3’ sequence of |3- 
actin was they key in the interaction and thereafter translocation (42). In 2003, the Singer 
group tested truncated ZBP-1 variants to determine the domains that are involved in 
binding the RNA, and found the truncated variant containing KH3 and KH4 bound as 
well as the full length ZBP-1 to the established 5'-ACACCC-3' sequence (41). They also 
performed a SELEX experiment where they found a consensus sequence of 5'-RCACCC- 
3' (R -  pyrimidine), which competed as well as the 5'-ACACCC-3' sequence (41).
The Nielsen group performed IMP-1 granule precipitation, and analyzed the 
associated mRNA by microarray analysis and found 671 associated transcripts (116). 
From these six hundred seventy one transcripts, three hundred and seven were selected as 
positive hits, based on sequences being able to be retrieved from NCBI Entrez, containing 
less than 1% unknown nucleotides, and sequences less than 5000 nucleotides in length 
(116). They then searched for these seven nucleotides in length motifs (a “word”), to see 
if  any of the 307 transcript share a common word, and found that these IMP-1 targets 
enrich a CCYHHCC (Y = C or U and H = C or U or A) motif (116).
Hafner et al. performed PAR-CLIP (Photoactivatable-Ribonucleoside-Enhanced 
Crosslinking and Immunoprecipitation) to assess RBP recognition elements (RREs) for
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FLAG/HA-tagged IMP-1, IMP-2 and IMP-3 (117). After PhyloGibbs analysis, a RRE
sequence of CAUH (H = A, U, or C) was found in more than 75% of the top 1000
clusters from 100,000 sequences clusters recognized by the IMPs (117).
As the research for a primary sequence recognized by the VICKZ family has
progressed from 1997 by the Singer group, to 2010 by Hafner et a i, there has been a
decreased in the specificity of the sequence (Table 15) (42, 117). Based on this, it is
unlikely that the primary sequence alone is recognized by the VICKZ family of RBPs.
Table 15. The progression of RNA primary sequence associated with the VICKZ
family of RNA Binding proteins.______________________________________________
Sequence Odds of sequence
5’-RCACCC-3' (R = Pyrimidine) (41
CAUH (H = A, U, or C) (117)
To date, there has been little or no effort in finding consensus secondary or 
tertiary structure of RNA recognized by RBP. This is in part due to the complexity 
associated with potentially sorting through a massive amount o f information to find the 
tentative structure. In addition, further challenges may arise when there is lack of 
knowledge on determined RNA secondary and tertiary structure. However, investigation 
into predicted structures of a group of RNAs bound by a common RBP may yield 
valuable information. To this end, the goal of this investigation is to compare and contrast 
the predicted structure of a group of oncogenic RNAs known to bind CRDBP.
4.1 Methodology
The sequences for the six RNA fragments that are known to bind CRDBP are: c- 
myc 1705-1792 (88 nts) (56), MITF 1621-1709 (89 nts) (Chapter 2, this thesis), Kras
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240-332 (93 nts) (Mackedenski S, unpublished results), CD44 2861-2958 (98 nts) (107),
MDR-1 790-881 (92 nts) and GLI1 307-393 (87 nts) (Table 16) (108).
Table 16. Oncogenic RNAs with high affinity for CRDBP.____________________
Name and RNA Sequence (5’-to-3')
Nucleotide 
Positions of RNA 
(Size)
MITF 1621-1709 UUUGCGUCAGAGAAAUGUCUGUCCAUUUUUAUUC
(89nts) AGGGGAAACUUGAUUUGAGAUUUUUAUGCCUGUG
ACUUCCUUGGAAAUCAAAUGU
CD44 2861-2958 
(98nts)
GAAAUUAGGGCCCAAUUAAUAAUCAGCAAGAAUU
UGAUCGUUCCAGUUCCCACUUGGAGGCCUUUCAU
CCCUCGGGUGUGCUAUGGAUGGCUUCUAAC
GLI1 307-393 AUGCCAGCCUGGACCUGCAGACGGUUAUCCGCAC
(87nts) CUCACCCAGCUCCCUCGUAGCUUUCAUCAACUCGC
____________________ GAUGCACAUCUCCAGGAG_________________________
The following programs were used to determine the secondary or tertiary structure 
of the six RNAs listed in Table 2: Mfold, RNAfold, Sfold, CARNAC, MC-FOLD/MC- 
SYM and LocARNA. The following are the websites where the in silico analysis were 
performed:
Mfold: http://mfold.ma.albany.edu/?q=mfold/RNA-Folding-Form (118)
RNAfold: http://ma.tbi.univie.ac.at/cgi-bin/RNAfold.cgi (119)
(Incorporating chemical modification constraints into a dynamic programming algorithm 
for prediction of RNA secondary structure.)
Sfold: http://sfold.wadsworth.org/cgi-bin/sma.pl (120)
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LocARNA: http://ma.informatik.uni-freiburg.de/LocARNA/Input.jsp (121)
CARNAC: http://bioinfo.lifl.fr/cgi-bin/RNA/camac/camac.py (104)
MC-FOLD/MC-SYM: http://www.major.iric.ca/MC-Fold/ (106)
The parameters for each of the RNA folding software were kept at default, unless 
there were specific options that needed to be specified, in which case the folding was 
performed for each of the options.
Mfold
The default parameters consist of the sequence being linear, folding temperature 
remains fixed at 37°C, ionic conditions at 1M NaCl, no divalent ions, 5% sub-optimality 
structures (considers structures within in 5% of the minimal free energy), an upper bound 
of 50 total structures, default window parameter (sequence length of 50-119 =default 
window size of 2, a smaller number represents more computed folding closer to each 
other, where a larger number computes less structures that are very different from each 
other), maximum interior/bulge size of 30, maximum asymmetry of an interior/bulge loop 
of 30, and no limit on the maximum distance between paired bases.
RNAfold
The default minimum free energy function was chosen, with the option to avoid 
isolated base pairs (prevents undesirable helices of length 1), dangling end energies 
assigned to free nucleotides on both sides of a helix in any case, RNA energy parameter 
from Turner model 2004, RNA molecule is assumed to be linear, and the default 
temperature of 37°C.
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Sfold
The default parameters consist of the sequence being linear, folding temperature 
remains fixed at 37°C, ionic conditions at 1M NaCl, no divalent ions, and no limit on the 
maximum distance between paired bases.
LocARNA
No RNA prediction folding parameters were provided, and a global standard 
alignment type and mode format was used.
CARNAC
In the CARNAC program the option of having the GC threshold enabled or 
disabled was required. Therefore, both options were performed. When GC threshold is 
enabled, it allows CARNAC to use variable energy thresholds for stems according to the 
average GC percent of the involved sequence.
MC-FOLD/MC-SYM
For the MC-FOLD program, the options of specifying to consider pseudoknots 
enabled and disabled were both performed. The default parameters for MC-FOLD, not 
considering H-type pseudoknots were to return the best 1000 structures with 
consideration for the best 15% sub-optimal structures. The default parameters for MC- 
FOLD when considering H-Type pseudoknots were to return the best 20 structures with 
consideration for the best 15% sub-optimal structures. The top structures were then 
directly pipelined into MC-SYM.
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4.2 Results 
Mfold
Using Mfold on c-myc 1705-1792 (88 nts) RNA, only one possible structure was 
generated. As shown in Table 17, the structure has five stem regions, one loop, and eight 
bulges, and has a AG of-14.10kcal/mol. Input of MITF 1621-1709 (89 nts) RNA 
generated five possible structures, with the most stable structure having a AG of - 
14.20kcal/mol, three stem regions, one loop and seven bulges (Table 17). The Mfold 
result for Kras 240-332 (93 nts) RNA showed three possible structures. Of these three 
structures, the second structure was most stable, having three stems, one loop and four 
bulges with a AG of-18.90kcal/mol (Table 17). The CD44 2861-2958 (98 nts) RNAs 
most stable structure of three had a AG of -22.50kcal/mol with four stems, two loops and 
four bulges (Table 17). There were two structure generated for MDR-1 790-881 (92 nts) 
RNA and the most stable structure had three stems, one loop and four bulges with a AG 
of -20.20kcal/mol (Table 17). For GLI1 307-393 (87 nts) RNA a single structure was 
predicted with four stems, two loops, four bulges and a AG of-13.95kcal/mol (Table 17).
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Table 17. Structures generated with Mfold of the six oncogenic RNAs.
Name Structure
Number of 
Stems, Loops, 
Bulges
Total Energy 
(AG) 
(kcal/mol)
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RNAfold
As shown in Table 18, RNAfold predicted one structure for each of the six 
sequences. Each of these structures has an associated base-pair probability for each of 
the nucleotides within the structure, as indicated with colours ranging from blue (zero 
probability) to red (100% probability).
Table 18. RNAfold geners
Name
ated structures of the six oncogenic RI
MFE Base-pair Probabilities
c-myc 1705-1792 (88nts) 0 * 0 0 0 0 “ °
MITF 1621-1709 (89nts)
c?  =»
1 0 2
Kras 240-332 (93nts)
CD44 2861-2958 (98nts)
MDR-1 790-881 (92nts)
GLI1 307-393 (87nts)
0
Sfold
For each sequence input into Sfold statistical RNA folding, ten possible structures 
are given as outputs with their associated lowest free energy (AG) as well as the sample 
frequency. As shown in Table 19, the first of ten structures for c-myc 1705-1792 (88 nts) 
RNA had a AG of -14.10kcal/mol and 0.499 sample frequency, suggesting this structure 
as the most likely of the ten predicted. Although the first MITF 1621-1709 (89 nts) RNA 
structure had the lowest AG of-14.50kcal/mol and a sample frequency of 0.192, the
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second structure had a greater frequency of 0.226 with a AG of -13.10kcal/mol (Table 
19). The MITF 1621-1709 (89 nts) RNA structure number three also had a greater 
sample frequency than that of structure one at 0.212, but had an even lower AG of - 
11,70kcal/mol. From the ten structures predicted for K-ras 240-332 (93 nts) the first 
three structures had sample frequencies of 0.195, 0.240 and 0.249 and AG’s of - 
19.20kcal/mol, -17.60kcal/mol and -16.10kcal/mol, respectively (Table 19). For CD44 
2861-2958 (98 nts) RNA sequence, the second structure had a sample frequency of 0.276 
and a AG of -21.30kcal/mol in comparison to structure one and three with sample 
frequencies of 0.118,0.260 and AG’s of -23.10kcal/mol and -19.60kcal/mol respectively. 
The MDR-1 790-881 (92 nts) RNA structure one had the highest sample frequency of 
0.298 and lowest AG of -18.80kcal/mol in comparison to structures two and three with 
sample frequencies of 0.269, 0.212 and free energies of -17.40kcal/mol and - 
16.10kcal/mol respectively (Table 19). For GLI1 307-393 (87nts) RNA, structure two of 
ten had the highest sample frequency of 0.301 with a AG of-16.50kcal/mol, whereas 
structures one and three has sample frequencies of 2.07, 0.199 and lowest free energies of 
-17.80kcal/mol and -15.20kcal/com respectively (Table 19)
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I Table 19. Sfold generated secondary structures of the six oncogenic RNAs.
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MC-FOLD
From MC-FOLD, the top one hundred structures not containing pseudoknots (no 
pseudoknots), and top twenty containing pseudoknots were generated. From those, the 
top one structure of both no pseudoknots and pseudoknots were compiled into a table 
alongside the top pseudoknot structure, which could be folded into tertiary structure using 
MC-SYM (Table 20). The non-pseudoknot structure for c-myc 1705-1792 (88 nts) RNA 
has four stems, three loops and one bulge, with three of the four stems coming together at 
a three-stem junction (Table 20). The top pseudoknot structure for c-myc 1705-1792 (88 
nts) RNA has three stems, two loops and three bulges, but was unable to have a tertiary 
structured predicted by MY-SYM (Table 20). Pseudoknot structure number four of c- 
myc 1705-1792 (88 nts) RNA, having one less bulge could be folded by MC-SYM, but 
predicted MC-FOLD structures numbered one to three could not (Table 20).
The MITF 1621-1709 (89 nts) RNA was predicted to have a three-stem junction 
with two loops and two bulges (Table 20). The top pseudoknot structure for MITF 1621- 
1709 (89 nts) RNA does not show a three-stem junction, but retains three stems, and has 
three loops and one bulge (Table 20). The fifth pseudoknot structure of MITF 1621-1709 
(89 nts) RNA with three stems, two loops and one bulge could be folded by MC-SYM 
into three-dimensional structure, but predicted MC-FOLD structures one to four could 
not (Table 20). K-ras 240-332 (93 nts) RNA had one consecutive structure as the top 
structure for both the no pseudoknots and pseudoknots option (Table 20). This conserved 
structure has three stems, which form a junction, with two loops and one bulge, and also 
managed to be formed into a tertiary structure by MC-SYM (Table 20). The top non­
pseudoknot structure for MDR-1 790-881 (92 nts) RNA has two stems, two loops and
I l l
one bulge, in comparison to the top tertiary folded pseudoknot structure with two stems, 
one loop and three bulges (Table 20). Both CD44 2861-2958 (98 nts) and GLI1 307-393 
(87 nts) RNAs were unable to be folded by MC-FOLD, as structures were determined to 
be too highly branched, and form the available computing power would take too long to 
resolve (Table 20).
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Table 20. MC-FOLD Top 1 from 100 non-pseudoknot and Top 1 from 20
pseudoknot and Top Pseudoknot structure folded in M<C-SYM.
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Structure
Top Pseudoknot Structure MC-SYM Computable 
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MC-SYM
The top pseudoknot structures from MC-FOLD were pipelined into MC-SYM to 
determine possible tertiary structure (Table 20). Once MC-SYM had predicted the 
possible tertiary structures (not exceeding one thousand structures), each of these 
structures under went a four series of minimization, in order to ensure if any 
discontinuous stretches of RNA are present in the model, that they are placed correctly. 
The structures were then ranked on Pscore, lowest free energy, van der Waals and 
electrostatics. Additional analyses such as base-pair interactions and estimated volume 
was also determined.
The fourth top pseudoknot structure for c-myc 1705-1792 (88 nts) out of twenty 
could be folded into tertiary structure by MC-SYM (Table 20). MC-SYM provided 127 
possible tertiary structures for this one MC-FOLD secondary structure. These 127 
structures were then minimized and ranked, highlighting structure number four of 127 
because it consistently ranked above the other across the different scoring methods (Table 
21). This tertiary structure had a Pscore of -49.50 ranking 1/127, a AG of -58.29kcal/mol 
ranking 2/127, and 6/127 for van der Waals and electrostatic interaction (Table 21).
The fifth top pseudoknot structure of MITF 1621-1709 (89 nts) RNA out of 
twenty had possible tertiary structure as determined by MC-SYM, with 1000 possibilities 
(Table 20). Structure three of 1000 ranking consistently highest in the three categories 
with a Pscore of -59.34 (2/1000), a AG of -61.72kcal/mol (4/1000) and 2/1000 for van der 
Waals and electrostatic interactions (Table 21).
The top MDR-1 790-881 (92 nts) RNA pseudoknot structure of twenty provided 
three possible tertiary structures (Table 20). Structure one of three was the top structure
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for Pscore (-52.88), lowest free energy (-63.09kcal/mol) and Amber calculation (van der 
Waals and electrostatic interactions) (Table 21).
MC-SYM predicted 95 structures for the top Kras 240-332 (93 nts) RNA 
pseudoknot structure (Table 20). The further Kras structure of 95, ranked second for the 
three analyses with a Pscore of -51.51 and a AG of -67.84kcal/mol being consistent in 
comparison to the structures (Table 21).
MC-SYM tertiary structure determination was not possible for CD44 2861-2958 
(98 nts) and GLI1 307-393 (87 nts) RNAs due to the inability o f MC-FOLD to provide 
any secondary structures (Table 20 and 25).
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Table 21. MC-SYM Tertiary Structure Information with possible H-type pseudoknots.
Name Structure Pscore Total Energy Amber Data Base pair Data Volume(-ellipsoidal)
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MDR-1
770-
881
(92nts)
#1/20
-52.88
(#1/3)
-63.09kcal/mol
(#1/3)
-21702.2750
(#1/3)
Tbs = 92 
Tprs = 39 
Std W.C = 23 (59%) 
WWc = 11 (28.2%) 
HSt = 1 (2.6%)
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GLI1
307-
393
(87nts)
UD*
*UD indicates undetermined due to the inability of MC-FOLD to produce secondary structure that are required to be pipelined into 
MC-SYM.
LocARNA
From the simultaneous folding and alignment o f the six RNA sequences of 
interest, LocARNA identified a possible shared stem region indicated in the alignment 
and structure (Table 22). Since LocARNA has a 2000 base-pair limit, 2000 base-pairs 
surrounding each of the six RNAs regions of interest was also input into LocARNA, and 
it shows on a larger simultaneous fold and alignment scale that there are conserved 
regions o f secondary structure shared by these RNA (Table 23). In Table 24, a non­
binding Kras sequence nts 148-239 (92 nts) was input into LocARNA in addition to the 
other six RNA sequences, and a shared stem of length 3 was predicted.
Table 22. LocARNA results from the six oncogenic RNAs.
Alignment Conserved Secondary 
Structure
K-raB 93nts 
Gli 87nts 
HlTF_89nts 
C-myc 88nts 
CD44 78nts 
MDR-T 92nts
K-ras 93nts 
Gli 87nts 
MITF 89nts 
C-myc 88nts 
CD44 78nts 
MDR-T 92nts
 (<<((( ))>))>.......
AUAUGAUCCAACAAUAGAGGA-UUCCUACAGGAAGCAAG-UAGUAAUUGAUGGA-GAAAC 5 7
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Table 23. LocARNA results from 2000 bps surrounding the smaller regions of 
interest of the six oncogenic RNAs. The table includes the alignment and shared 
secondary structure._____________________ _______________________________
Alignment Conserved Secondary Structure
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Table 24. LocARNA results from the six oncogenic RNAs.
Alignment Conserved Secondary 
Structure
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UUUGCG— UCAGAG-AAAUGUCUGU-CCAUU-UUUAUUC-AGGGGAAA-Q3U--GAUUU- 50  
AUAUGA— UCCAAC-AAUAG-AGGAUUC-CU— A-CAGGAAGCAAGUA-GQA— AUUGAU 49
. 1 0 . . 2 0 . . 3 0 . . 4 0 . . 5 0 .
•)))....................................................
— -CUGGAAGACAAA--UACACAAA-AU-U--------- AGAAAACAGUUUUU— UC 91
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GGAGA-AACCUGUCUCTJ— -UGGAU-AU-UCUCGACACAGCAGGUCAU— GA 9 3 
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CARNAC
CARNAC has two options to compute the hypothetically conserved RNA 
secondary structure, without or with a GC threshold, and therefore both options were 
performed. Without the GC threshold, the clustal alignment did not show any conserved 
secondary structure, but CARNAC did provide a stem region for c-myc 1705-1792 (88 
nts), MDR-l 790-881 (92 nts) and GLI1 307-393 (87 nts) as shown in Table 25. When 
the GC threshold was enabled, CARNAC found a conserved stem region shared for c- 
myc 1705-1792 (88 nts) and GLI1 307-393 (87 nts) and a different conserved stem region
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for MITF 1621-1709 (89 nts), Kras 240-332 (93 nts), CD44 2861-2958 (98 nts) and
MDR-l 790-881 (92 nts) (Table 26). The predicted conserved stems are illustrated
alongside the predicted whole structure (converted from Dot-Bracket format using
Mfold) (Figures 45 and 47).
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Figure 45. Predicted Dot-Bracket Structures from CARNAC without GC Threshold 
Enabled. These were input into Mfold and displayed in Table 25.
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Table 25. Predicted shared stem regions of RNA alongside the predicted secondary
structure of RNA without GC Threshold Enabled in CARNAC.
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* The stem regions and secondary structure was prec icted by CARNAC. The structure
for the RNA sequences were generated using Mfold from Dot-Bracket Structures.
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Figure 46. Clustal Alignment by CARNAC with GC Threshold Enable, displaying 
the nucleotide composition above and dot-bracket secondary structure information below 
of the six oncogenic RNAs.
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Figure 47. Predicted Dot-Bracket Structures from CARNAC with GC Threshold 
Enabled. These were input into Mfold and displayed in Table 26.
Table 26. Predicted shared stem regions of RNA alongside the predicted secondary 
structure of RNA with GC Threshold Enabled in CARNAC.
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*The stem regions and secondary structure was predicted by CARNAC. The structure
for the RNA sequences were generated using Mfold from Dot-Bracket Structures.
4.3 Discussion
From the analysis using Mfold and RNAfold, there does not appear to be a single 
consensus secondary structure for the six RNA sequences being compared. When 
comparing between the multiple structures generated for a single sequence by Mfold, one 
can see that the structures with the most stem regions have the lowest free energy, 
corresponding to highest stability. The results from Sfold suggest that there are multiple 
structures co-existing and changing between each other, instead of a single structure that 
each of the RNA sequences occupy. This also indicated that the most stable structure due 
to energy calculations isn’t always the statistically most common structure present either. 
Between these three folding software, Mfold, RNAfold and Sfold one can also notice the 
same and very similar structures being produced as representative structures, because 
these programs are folding the RNA under the same MFE models and biophysical 
principles.
For c-myc 1705-1792 (88 nts) the exact same structure was produced for Mfold, 
RNAfold and the first structure in Sfold. The shared stem structures are at nucleotides
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10-13 with nucleotides 78-81, nucleotides 17-19 with nucleotides 73-75, nucleotides 25- 
27 with nucleotides 67-69, nucleotides 32-34 with nucleotides 60-62 and nucleotides 39- 
42 with nucleotides 50-53 (Tables 21-23, SI and S2). The shared bulges between Mfold, 
RNAfold and Sfold of c-myc are located at nucleotides 14-16,28-31, 35-38, 54-59, 63- 
66, 70-72 and 76-77 (Tables 21-23, SI and S2). One shared end loop was located at 43- 
49 and two free ends at the 5' and 3' ends respectively nucleotides 1-9 and 82-88 (Tables
21-23). The two most conserved stem regions that were maintained in the ten different 
structures folded in Sfold were at nucleotides 32-34 and 39-42, which consistently 
maintained the adjacent bulges at nucleotides 35-38, 54-59 and the one end loop at 43-49 
(Tables 21-23, SI and S2). The consensus structure for c-myc 1705-1792 (88 nts) 
between these three programs is then the first structure generated by all three programs. 
This structure contains four stem regions, eight bulges, one stem loop and two free ends 
with a AG of-14.10kcal/mol and from Sfold a 0.499 sample frequency (Tables 21-23). 
Previous research using enzymatic digestion to determine secondary structure of c-myc 
RNA 1705-1792 validates the structure that has been generated by Mfold, being the same 
as Sfold and RNAfold (Figure SI) (5).
For MITF 1621-1709 (89 nts) the first Mfold structure of five was identical to the 
first Sfold structure (Tables 21 and 23). The RNAfold structure was identical to the third 
Sfold structure with an additional stem in the Sfold structure at nucleotides 1-4 with 83- 
86 (Tables 22 and 23). Between these two structures, (the first Mfold/Sfold and third 
Sfold/RNAfold structures) there were no shared stem regions, but a similar stem 
morphology arose making a symmetrical G-bulge in the middle of a stem region (Table 
17 and 23). Shared identical bulges by these two structures were at nucleotides 26-32
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and 66 (Table S2). Shared impaired nucleotides were 1-5, 57-58, 62, 70-75, 80-89 and 
morphological sequence at two different stems with a sequence of GAAA at nucleotides 
39-42 and 12-15 in the Mfold/Sfold structure 1 and RNAfold/Sfold structure 3 
respectively (Tables 21-23, SI and S2). From the additional Sfold information, Sfold 
structure 1 has a sample frequency of 0.192, being a little lower than 0.212 of Sfold 
structure 3. There is no consensus between these two structures other than sharing a 
symmetrical G-bugle in the middle of a stem.
For the Kras 240-332 (93 nts) structures, the second Mfold structure, is almost 
identical the RNAfold structure with one additional unpaired nucleotides at 34 and 61 
(Table 17 and 22). This Mfold structure shares almost all of the same unpaired and 
paired nucleotides with the second Sfold structure (Table 17 and 22). Two differences 
are the unpaired nucleotides at 34 and 61, as well as paired nucleotides at 39 with 56 in 
the Mfold structure, which is not so in the Sfold structure (Table 17 and 22). The stem 
regions shared by these three very similar structures encompass nucleotides 2-8 with 86- 
92, 17-22 with 71-76, and 28-39 with 56-67 (Table SI). The shared bulges are 
nucleotides 9-16, 23-27, 33, 37, 58, 62, 68-70, and 77-85 (Table S2). There was one 
stem loop, for all three structures, which remained the same, spanning nucleotides 40-55 
(Table 17-23 and S2). All three structures also retained a single adenine nucleotide at 
both the 5' and 3' ends (Tables 17-23). Between these three programs, a consensus 
structure for Kras 240-332 (93 nts) became apparent, with three stems, six bulges and a 
single stem loop (Tables 21-23).
For the CD44 2861-2958 (98 nts) the first Mfold structure has a single difference 
from the RNAfold structure, being unpaired nucleotides 20 with 40 (Tables 17 and 22).
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This Mfold structure also has a single difference from the first Sfold structure, being 
unpaired nucleotides 13 and 46 (Tables 21 and 23). The conserved stems shared by these 
predicted structure are at nucleotides 8-10 with 49-51, 18-26 with 34-42, and 54-70 with
75-97 (Table SI). The single stranded bulge and stem loop nucleotides shared by all 
three structures are at nucleotides 1-7,11-12,14-17,21,27-33,43-45,47-48, 52-53,63, 
88, and 98 (Table S2). From Mfold, Sfold and RNAfold, CD44 2861-2956 (98 nts) has a 
consensus structure composed of two major stems broken up with eight bulges and two 
stem loops (Tables 21-23). The first Mfold structure of CD44 2861-2956 (98 nts) is also 
in agreement with experimentally determined structure (Figure S2) (6).
The first Mfold and Sfold structures for MDR-l 790-881 (92 nts) are identical, 
where as the third Sfold structure shares all the same features as the RNAfold structure 
with the addition of a base pair at G56 with C62, which is also seen in Mfold and Sfold 
structure one (Tables 21-23). The shared stem regions generated for these similar 
structures are nucleotides 2-5 with 83-86, 11-16 with 73-78, and 17-36 with 42 to 54 
(Table SI). Conserved bulges for MDR-l generated structures were at nucleotides 6-10,
22-28, 34, 44, 55, 57-61, 63-72, and 79-82 (Table S2). A shared stem loop region of 
UUU at nucleotides 38-40 is maintained and two free ends at nucleotides 1, and 87-92.
For GLI1 307-393 (87 nts) the Mfold and first Sfold structures are identical, and 
the RNAfold structure is similar with the introduction of an additional stem region 
(Tables 21-23). This extra stem region present in RNAfold comes from pairing of 
nucleotides 59-62 with 70-73 and pairing 76-77 with 16-17 instead of having 59-62 and
76-77 unpaired while 16-19 is paired with 72-75 as seen in Table 3. Shared stem regions 
between these two structures are nucleotides 8-17 with 74-85, nucleotides 22-24 with 29-
130
31, and nucleotides 42-45 with 53 to 56 (Table SI). Shared bulges for GLI1 are 
nucleotides 14-15,18-21, 32-41, 57-58, and 78-79 (Table S2). Free nucleotides shared 
by both structures for GLI1 are 1-7, 63-69, and 86-87 as in Table 17, 22 and 23. 
Conserved stem loops were 25-28 and 46-52 (Table S2).
When comparing the generated structures of all six RNAs between each other 
using Mfold, Sfold and RNAfold, all the RNAs formed these long “rod-like” structures 
with one or two stem loops (Tables 21, 22, 23). GLI1 307-393 (87 nts) and CD44 2861- 
2956 (98 nts) could be exceptions to this having the possibility of forming three stem 
loops as seen in the RNAfold structures (Table 18). Another similarity between all these 
structures is the majority of the free nucleotides (making them available to hydrogen 
bond with protein) mainly consist of adenine, cytosine, and uracil, which is what has 
been reported earlier (Table 15, Table S2).
The MC-FOLD software strays away from these MFE models in a way by 
accounting for non-canonical base pairs, which is not account for by Mfold, RNAfold 
and Sfold. Instead MC-FOLD uses statistics on nucleotide cyclic motifs from the Protein 
Data Bank of known crystallized RNA motifs, explaining why the results generated are 
different by comparison to that of Mfold, Sfold and RNAfold. Although the results are 
somewhat different, again the overall structures for the RNA maintain these “rod-like” 
structures (Table 20). For CD44 2861-2958 (98nts) RNA and GLI1 307-393 (87 nts) 
RNA are determined “too highly branched” for MC-FOLD to output, and this branching 
can also be seen in the RNAfold structure of GLI1 307-393 (87 nts) (Table 20). The MC- 
FOLD structures have stem loop regions mostly consisting of two to three nucleotides 
where as the MFE based programs rarely predict stem loops less than four nucleotides
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(Tables 21-24). The MC-FOLD predicted structures also consistently contained less and 
smaller bulge regions, in comparison to the MFE-based generated structures (Tables 21- 
24).
Interestingly, from the tertiary data on all four structures generated indicate some 
form of an L-type structure (Table 21). For both MITF and Kras RNAs, this L-type 
structure is very evident, and looks very similar to each other (Table 21). This L-type 
structure can also be identified in the c-myc RNA structure with an additional helical 
stem loop protruding from one side (Table 21). For MDR-l, this L-type structure is more 
exemplified as a curved V, but again illustrates a similar overall type of fold (Table 21).
Both LocARNA and CARNAC indicated that these six RNAs sequences 
unrelated in gene product and evolutionary history, do share elements of conserved 
secondary structure. LocARNA indicated this with a single stem that all six RNA 
sequences can form (Table 22). However, the single shared stem generated by 
LocARNA arise after gaps are inserted into sequences and LocARNA tries to account for 
all the input RNAs to share some feature (Table 22). The stem predicted by LocARNA 
was not present in any of the predicted secondary structures. The results of LocARNA 
are weakened by the additional o f gaps within sequences and having the inability to 
distinguish similar and dissimilar RNAs into distinct groups (Tables 26 and 28). The 
addition of a non-binding RNA sequence, Kras 148-239 (92 nts), illustrates that 
LocARNA is unable to distinguish which RNA sequences should be grouped together 
before folding, but instead will add gaps to the sequence alignment until the primary 
sequences can account for a shared secondary structure feature.
132
The CARNAC results indicated that there is a conserved stem shared by c-myc 
1705-1792 (88 nts), and GLI1 307-393 (87 nts) with or without the GC threshold present 
(Table 24). A shared stem for MDR-l 790-881 (92 nts) was also made in the absence of 
the GC threshold, but from the alignment there was no indication of any conserved 
structure (Figure 45, Table 25). With the GC threshold enabled, MDR-l 790-881 (92 
nts) shares a conserved stem with MITF 1621-1709 (89 nts), Kras 240-332 (93 nts) and 
CD44 2861-2958 (98 nts) as a separate group from c-myc 1705-1792 (88 nts) and GLI1 
307-393 (87 nts) (Figure 46, Table 26). CARNAC also produced dot-bracket format of 
the entire RNA secondary structure it predicted which was manually input into Mfold 
(Figure 45 and 47) and illustrated against the predicted shared stem regions (Table 25 and 
30). The shared stems that are generated indicate that after an alignment of the primary 
sequences, stem regions at the same nucleotide numbers form stems. This information is 
limited to producing useful results only when the RNAs are going to form identical or 
very similar secondary structures. In the case where only a single stem region is shared 
at the same nucleotide position, no other useful information is gained, as these stems do 
not share the same chemical information.
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5. General Discussion 
5.1 General Overview
To understand the functions of CRDBP during embryonic and cancer 
development through interaction with RNA via its four KH domains, we aimed at 
investigating the targeted RNA molecules as well as identifying which of the four KH 
domains are important. Understanding the RNA molecules that interact with CRDBP 
began by mapping smaller RNA regions of MITF 1330-1740 (411 nts), c-myc 1705-1886 
(182 nts), MAPK 2764-4713 (1949 nts), and P-TrCPl (863 nts). Knowledge of these 
smaller regions of RNA was then used in silico analysis, and in the design of antisense 
oligonucleotides (AONs) as inhibitors of CRDBP-MITF RNA interaction. In addition, 
such knowledge should pave the way for future development of fluorescent polarization 
method to study CRDBP-RNA interaction and to screen for inhibitors of CRDBP-RNA 
interaction. The second goal of this investigation was to understand how the four KH 
domains interact with each other in facilitating CRDBP binding to RNA targets. The 
significance of the KH domains was investigated by introducing a single point mutation 
at the first glycine in the G-X-X-G motif to an aspartate (D-X-X-G). In general, this 
study is expected to expand our current knowledge on how CRDBP and other KH 
domain-containing RBPs function and provide future researchers with additional tools 
and insights into the design of compounds (nucleic acid-based and small organic 
molecules) for the inhibition of protein-RNA interaction.
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5.2 Mapping RNA
From the RNA mapping studies, the smallest region of c-myc RNA that still binds 
CRDBP is 1735-1792 (58 nts). The smallest MITF RNA that retained binding to 
CRDBP is 1621-1740 (112nts). From the 1949 nt MAPK 3’-UTR region, four regions 
were identified for having the ability to bind CRDBP, 2764-3089 (326 nts), 3723-4063 
(341 nts), 4036-4386 (351 nts) and 4368-4713 (346 nts). As for the p-TrCPl RNA, the 
smallest region showing binding with CRDBP is 1131-1219 (89 nts).
The knowledge of mapped small RNA regions from several RNAs that bind 
CRDBP, including Kras RNA performed in Dr. Lee’s lab (Mackedenski S, unpublished 
observation) has assisted in silico analysis in the present study. The in silico analysis is 
discussed in greater detail in section 5.6.
The smaller regions of MITF, c-myc, MAPK, and P-TrCPl RNAs that have been 
mapped will further aid in future studies aimed at developing a high-throughput 
fluorescent polarization method to screen libraries of small molecule for ability to inhibit 
the CRDBP-RNA interaction. The fluorescent polarization method requires that small 
RNA be fluorescently-tagged for use as substrate. In fact, a recent study showed that 
small molecules can be screened for ability to break protein-RNA interaction using 
fluorescent c-myc RNA as substrate in fluorescent polarization method (122).
Another type of CRDBP-RNA inhibitor, that also takes advantage of the 
knowledge of smaller regions of RNA, is antisense oligonucleotides (AONs). The design 
of AON is based on the knowledge of smaller region of RNA that’s binds CRDBP.
These AONs interrupt the binding of CRDBP by targeting the RNA of interest via the 
formation of dsRNA segments. These dsRNA regions are expected to hinder the normal
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RNA interaction with CRDBP’s KH domains. Alternatively, such dsRNA region may be 
recognized and cleaved by enzymes, as was demonstrated for the siRNA-mediated 
pathway. Two research groups have indeed demonstrated that AONs are capable of 
breaking the CRDBP-RNA interaction. One group was targeting the CRDBP-c-myc 
RNA interaction and the other was targeting the CRDBP-CD44 RNA interaction (107, 
123).
5.3 Investigating the Role of KH Domains of CRDBP in Binding RNA Targets In 
Vitro and in Cells
Prior research has shown that VICKZ family members interact with RNA through 
the KH domains as opposed to the RRM domains (39, 41, 72, 76). The manner in which 
the KH domains interact with RNA has been determined by studies on other KH-domain 
containing RBPs (2, 50, 72, 124). The studies illustrated the importance of the flexible 
G-X-X-G motif, and how the introduction of a negatively charged aspartate either at the 
first position (D-X-X-G), at the second and third position (G-D-D-G), or two negatively 
charged glutamate at the second and third position (G-E-E-G) of this motif interrupted 
the ability of the KH domain to bind RNA (112, 125, 126). Understanding which KH 
domains of CRDBP that interact with a specific RNA should provide valuable 
information on how CRDBP interacts with RNA in general. Such knowledge is also 
useful for future development of drugs that specifically target KH domains known to be 
important for interacting with specific RNA molecules.
The c-myc 1705-1886 (182 nts) RNA fragment lies within the CRD region and 
was one of the first RNAs to be shown to have high affinity for CRDBP (56). The ability
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of CRDBP to bind c-myc 1705-1886 (182 nts) RNA fragment was re-confirmed using 
EMSA and was compared to a panel of CRDBP G-X-X-G KH variants. Amongst the 
KH variants with a single mutation, KH1 showed a modest 2-fold reduction in binding 
with the 182 nts c-myc RNA as compared to the KH2, KH3, and KH4 variants, as well as 
the WT-CRDBP (Table 27).
Dr. Lee’s lab has previously assessed the variants with double KH mutations and 
found that CRDBP-KH1-2, KH1-3, KH1-4, KH2-3 and KH2-4 all exhibited no binding 
to c-myc 1705-1886 (182 nts) RNA, whereas CRDBP-KH3-4 showed binding profile 
which is similar to that of the WT-CRDBP (Table 27) (109). This loss of binding upon 
mutation at two KH domains reflects what has been previously reported for how the 
RBPs ZBP1, PCBP2 and FMR1 KH domains function as a pair. The ZBP1-RNA 
interaction has been previously described to utilize KH3 and KH4 domains in tandem to 
bind RNA (72). This was revealed by x-ray crystallography study, where the KH3 and 
KH4 domains of the truncated ZBP-l-KH-3-4 form an anti-parallel pseudodimer that acts 
as a binding surface for RNA (72). Chao et al also postulated that this pseudodimer 
would be present in the other VICKZ proteins as they have such a high degree of 
conserved amino acids (72). Interestingly, both PCBP2 and FMR1 also adopted 
intramolecular forces between their KH1 and KH2 domains in a similar anti-parallel 
pseudodimer topology (2, 124).
The MITF 1550-1740 (191 nts) RNA fragment showed binding to the KH1 
variant, although the binding coefficient could not be determined due to the relatively 
weaker binding and hence the inability to fit into a typical binding curve (Table 27). The 
CRDBP-KH3-4 bound to MITF RNA with similar affinity as the WT-CRDBP (Table
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27). The remaining CRDBP KH variants (KH2, KH3, KH4, KH1-2, KH1-3, KH1-4, 
KH2-3, KH2-4) showed no binding affinity to the MITF 1550-1740 RNA (191 nts)
(Table 27). Such results suggested that regions other than the G-X-X-G motif in the KH3 
and KH4 domains co-operatively function to interact with the MITF 1550-1740 RNA 
(191 nts). The data also suggested that all four KH domains play an important role in 
binding to the MITF RNA, and this appears to contradict the notion that the protein 
functions with two didomain KH groups (KH1-2 and KH3-4), and that KH1 and KH2 
work with each other in binding MITF RNA. An interesting observation made here was 
that while both CRDBP-KH3 and CRDBP-KH4 variants showed no binding with MITF 
RNA, the CRDBP-KH3-4 variant surprisingly exhibited binding to the same RNA. It is 
possible that regions other than the G-X-X-G motif in the KH3 and KH4 domains can 
somehow cooperate with each other to facilitate binding under situations where the G-X- 
X-G motif in both KH3 and KH4 domains are mutated. Further experimentation is clearly 
required to test this hypothesis.
Dr. Lee’s lab had previously examined the binding constants for CD44 and GLI1, 
and showed that these two RNA molecules also bind in a different manner as compared 
to c-myc and MITF RNAs (Table 27) (108). The comparison of the binding constants 
from all four RNA fragments shows that CRDBP binds uniquely to each o f the individual 
RNA molecules by utilizing different KH domains (Table 27). CRDBP interacts with 
different RNA molecules with various combinations of the KH domains, and this is in 
line with the role RNA structure plays in protein recognition. This is also in congruent 
with the idea that if primary sequences (recognized by KH domains) of RNA molecules 
are orientated so two or more KH domains are involved, a binding event would occur.
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This would also suggest there are minimal changes that need to place in the structures of 
both CRDBP and RNA when a binding event is taking place. Such a model is also 
consistent with the CD spectral data, which showed no noticeable change in RNA 
structure.
Table 27. A Summary of the Dissociation Constant Kd of Four RNAs that Bind 
CRDBP.
Variant MITF CD44 GLI1c-mvc
723.07 ±75.13 211.18 ±34.94
KH3 320.81 ±42.75 No Bindin 219.32 ± 19.35 466.18 ± 136.08
No BindmKH1-2 No Bmdm No Bindin No Bmdm
No Bmdm No Bmdm No BindinKH1-4
KH2-4 No Bmdm No Bmdm No Bindin No bmdm
“Adaptation from Table 9 in the MSc thesis of Mr. Kashif Mehmood (108).
UD denotes undetermined and symbolizes CRDBP variants that retained partial binding 
ability and could not have a Kd constant determined.
Using IP coupled with qRT-PCR method, Dr. Lee’s lab had previously shown that 
there is a reduction in the binding of CRDBP single KH variants to c-myc and CD44 
mRNAs in cells (109). As shown in Chapter 3, the CRDBP double KH variants 
exhibited even greater decrease in binding to the c-myc and CD44 mRNAs (Figure 37). 
An explanation for the differences observed between the inability of CRDBP KH variants 
to bind c-myc and CD44 mRNA in cells as compared to those single KH variants and 
CRDBP-KH3-4 variant that showed binding in vitro is then warranted. One would have 
to understand the complexity of what is occurring in cells as opposed to the simplicity of 
an in vitro system where only the protein and RNA molecule of interest are interacting.
As described by Nielsen et al, IMP1 has been shown to cooperatively and sequentially
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bind to RNA substrates in dimers in the process of forming ribonucleoproteins (RNPs) 
complexes; RNA + 2Protein <-> RNA-Protein, + Protein «-> RNA-Protein2 (45). This 
RNP complex aids in the stabilization between IMP1 and RNA substrate for cellular 
localization (45). If the interaction between CRDBP and the RNA are defective on a 
small scale, it could then prevent the formation of RNP complexes and result in defective 
binding required in cells.
5.4 The Attempt to Use Zebrafish Model to Understand the Significance of KH 
domains of CRDBP in Conferring an In Vivo Phenotype
One of the goals of this investigation was to correlate CRDBP function with 
phenotypic changes in Danio rerio (zebrafish). The zebrafish model was selected over 
other models because: (i) the ease in visualizing the embryos and adult zebrafish; (ii) a 
shorter time period for fish development that leads to rapid generation of data; (iii) 
having colleagues with expertise in zerbrafish experimentation; and (iv) most 
importantly, there was a previously observed phenotype, namely a reduction in 
pigmentation, in zebrafish upon injection of a specific morpholino against CRDBP in D. 
rerio (30). Upon injection of the morpholino, Goswami et al reported observations of 
decreased levels of mitfa (zebrafish MITF) mRNA which was followed 48 hours later by 
a reduction in cell pigmentation in zebrafish (30). For the purpose of this study, I made a 
number of selected CRDBP variant constructs in anticipation of studying their role in the 
zebrafish model. But unfortunately, the data published by Goswami et al could not be 
reproduced. It was discovered that the morpholino sequence designed by Goswami et al 
targeted IGFBP1 (Insulin-like growth factor-binding protein 1) mRNA and not the 
IGF2BP1 (CRDBP) mRNA. Furthermore, when a newly designed specific morpholino
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against zebrafish IGF2BP1 was injected into zebrafish embryos, no changes in 
pigmentation nor any observable phenotypes can be seen in the zebrafish. Hence, the 
earlier proposed investigation could not be carried out.
5.5 An Attempt to Use Circular Dichroism Spectroscopy to Understand CRDBP- 
RNA Interaction
The CD Spectroscopy was used to examine the possible CD spectral changes in 
RNAs upon interaction with CRDBP. Using two ratios of CRDBP to RNA 
concentration, no observable in CD spectra of RNA was seen. If any observations were 
made by this technique it would at best indicate that some interaction is taking place 
between CRDBP and RNA, by having changes present in the generated spectral graphs. 
Such changes, if  any, would not provide detailed information on how these two 
molecules interact. Rather, it would only complement the in vitro EMSA data that 
already illustrates there is an interaction between the protein and RNA.
5.6 In Silico Analyses of the Structure of RNAs that Bind CRDBP
From the in silico analysis using Mfold, RNAfold and Sfold, it is evident that 
RNA molecules do not form static structures, but instead multiple structures could co­
exist and be changing between these different possible structures. The Sfold predictions 
also indicated that it is not always the most stable structure with the lowest AG that is the 
most prevalent form. These three programs also generated very similar structures for the 
individual RNA molecules assessed, most likely because all three programs are based on 
similar biophysical principles of MFE models. In comparing the generated predicted 
structure of all RNA molecules using the three programs, an overall “rod-like” structure
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was consistently modeled. One high note about the data generated from these three 
programs alone (Mfold, RNAfold, Sfold) was not the structured regions, but instead the 
“unstructured” free nucleotides. It is common knowledge that guanines and cytosines 
form the strongest interactions by having three hydrogen bond pairs, and therefore are 
more likely to make up the majority of the structured stem regions. With most of the 
structured regions made up of G-C bonds, this left adenines, uracils to make up majority 
o f the free nucleotides. This indeed was the case that adenines and uracils with cytosines 
and the odd guanine made up most o f the free nucleotides for interaction with protein. 
These are also the nucleotides that make up the predicted primary sequences to interact 
with the VICKZ family of RNA binding proteins (Table 15).
As with the MFE-based programs, the MC-FOLD-MC-SYM pipeline also 
generated “rod-like” structures, but with base pairs from solved crystal structure data of 
other RNA molecules. An L-shaped structure was predicted for MITF and Kras RNA 
molecules, whereas the MDR-1 RNA structure resembled a more curved V-shape. The 
c-myc RNA also fit this L-type structure, with an additional stem loop protruding from 
one side.
In silico algorithms and computing power are not quiet powerful enough to act as 
a stand-alone prediction of secondary and tertiary structure. Additional 
secondary/tertiary probing data could be collected, but this kind of information does not 
always aid with in silico analysis. Although the in silico data is not conclusive; it did 
however help establish an idea on how the primary structure is spaced by the secondary 
structure, and serves as an additional tool to understand how CRDBP and other RNA 
binding proteins interact with RNA. This notion would require some means of acquiring
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RNA structural information, with and without bound protein possibly through x-ray 
crystallography trials. This could provide a more detailed examination of the protein- 
RNA interaction and has the potential to bridge the findings of those primary sequences 
with the importance of the overall RNA structure.
Currently, in silico analysis is also limited by the amount of primary sequence that 
can be computed at a time. When the in silico method of modeling RNA molecules can 
accommodate the entire RNA molecules, the relevance and reliability of this type of 
method would increase.
5.7 Future Directions
The results generated from this study have paved the way for further basic and 
applied research based on CRDBP-RNA interaction. Firstly, the design of AONs or 
sense oligonucleotides against smaller regions of the mapped RNAs (c-myc, MITF, and 
P-TrCPl) to inhibit specific CRDBP-RNA interaction is now possible.
From this study, it is clear that specific KH domains act together to uniquely bind 
to specific RNA molecules. Such knowledge should aid in the development of small 
molecule inhibitors against CRDBP-RNA interaction. One could also envision that these 
small molecule inhibitors could be designed to be selective for individual KH domains or 
specific sets of KH domains of CRDBP. This kind of selectivity would inhibit the 
binding of RNA molecules of interest to CRDBP by blocking the appropriate KH 
domains.
Currently from in vitro studies, the significance of the KH domain has been 
established as the key player in binding with specific RNA molecules. The use of cell
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lines for assessing the role of VICKZ family members to interact with RNA through the 
KH domains has also been recognized. Assessing CRDBP in cell lines have also been 
linked to a phenotypic change consisting of the formation of granules in the cytoplasm.
In the near future, it would be important to establish an in vivo model to further 
understand CRDBP-RNA interaction in the context of a whole animal. An in vivo model 
using CRDBP variants would translate the previously generated in vitro and cell data to a 
complex organism level, and better link the CRDBP-RNA association to a phenotype and 
disease. An animal model would also allow for the CRDBP-RNA complex to be 
assessed in a different context, one that accounts for new biological variables that 
simulate a biochemical environment closer to that of humans. A working animal model 
would also provide a more biologically relevant way to further assess small molecules for 
effectiveness at breaking the CRDBP-RNA interaction and the effects of the small 
molecules on an in vivo phenotype.
The in silico analysis should be complemented with validation of the RNA 
structure using experimental approaches and the RNA-protein interaction by 
crystallography trials. However, it should be kept in mind that current crystallography 
techniques also have limitations. Such limitations include the requirement for large 
amount of RNA sample, and guesswork at optimal crystallization conditions, which also 
tend to be non-native conditions that can produce structural artifact.
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5.8 Concluding Remarks
The knowledge of smaller regions of RNAs, as generated in this study, has 
provided researchers with additional tools to discover new inhibitory compounds against 
CRDBP function.
The in silico analysis has revealed some commonality in the structure of RNAs 
that bind CRDBP. It also established the idea that the positioning of the primary structure 
within the secondary structure could provide a suitable RNA binding surface for 
interaction with CRDBP.
This study confirmed the importance of the G-X-X-G motif in the KH domains of 
CRDBP in interacting with RNA. This study also clearly showed that CRDBP binds to 
different RNA molecules using different KH domains.
Collectively, the studies reported here should aid in future developments for the 
discovery of new mechanism in disrupting protein-RNA interactions involved in cancer 
and other diseases.
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Figure SI. Ribonuclease secondary structure probing of human c-myc CRD RNA 
nts 1705-1792 (88nts), indicating the locations of bases accessible for enzyme probes. 
Adapted from Tafech et al, 2007 (5).
C29M- -0914 CU
-2*4
G24M-csm-
G2fN~
2M7CA
2SMCA
•2mtAa*M-
G » lf -
G2M9-
1 2 34567 S
. *
‘S#
<sr
i.*
1 2 34 S i
B
3890
-2642CA 
-29J9 LO 
-2937 LC
•2926 C *
.2915 VC 
•2914 UU 
■2913 Cli 
•2911CA
•2994 CA
A—U
2880— E u
2920 2930
S  A A A u ?  A ® "0
CAAU CUUCG
r m V # u-
u AGGliA ^  G
2950 / 42940
CD44 RNA (nts 2861-2958)
Figure S2. Ribonuclease secondary structure probing of human CD44 RNA nts 
2861-2958 (98nts). Adapted from Kim et al, 2010 (6).
Table SI. List of all the base-paiured secondary structure features.
RNA Name Stem Structure of RNA
c-myc stem I 5’ CGGA 3' (nts 10-13) 
3' GCCU 5’ (nts 78-81)
c-myc stem II 5' GGA 3' (nts 17-19) 
3' CCU 5’ (nts 73-75)
c-myc stem III 5’ AUG 3’ (nts 25-27) 
3’ UAC 5' (nts 67-69)
c-myc stem IV 5' GGC 3' (nts 32-34) 
3' CCG 5' (nts 60-62)
c-myc stem V 5' AAGG 3' (nts 39-42) 
3' UUCC 5’ (nts 50-53)
MITF stem I 5' GUCA^AGAAAUG 3' (nts 6-17) 
3' CAGUr UCr r UAU 5' (nts 59-70)
MITF stem II 5’ GUC- -CA3' (nts 21-25) 
3' UAGaGU5' (nts 50-55)
MITF stem III 5' UCAGG 3' (nts 33-37) 
3' AGUUC 5' (nts 43-47)
Kras stem I 5' UAUGAUC 3’ (nts 2-8)
3' GUACUGG 5' (nts 86-92)
Kras stem II 5' GAGGAU 3' (nts 17-22) 
3' CUCUUA 5' (nts 71-76)
x ix
Kras stem III 5' CAGGAaGCAaGU 3' (nts 28-39) 
3' GUUCUr UGUr CA 5' (nts 56-67)
CD44 stem I 5' GGG 3' (nts 8-10) 
3' CCC 5 '(nts 49-51)
CD44 stem II 5' AAUaAUCAG 3' (nts 18-26) 
3' UUGr UAGUU 5’ (nts 34-42)
CD44 stem III 5' UUGGAGGCCUUUCAU------------- CC 3’ (nts 54-
70)
3’ AAUCUUCGG, ,AGGUA,irn, Ini,GG 5' (nts 75-97)
MDR-1 stem I 5' GCUG 3' (nts 2-5)
3’ UGAC 5' (nts 83-86)
MDR-1 stem II 5' CUGGUU 3 '(nts 11-16) 
3’ GAUUAA 5’ (nts 73-78)
MDR-I stem III 5' GCUGC 3' (nts 17-21) 
3' CGACG 5' (nts 50-54)
MDR-1 stem IV 5' CAGGUuUC 3' (nts 29-36) 
3’ GUCCG„GG 5' (nts 42-49)
GLI1 stem I 5’ CCUGGAccUG 3' (nts 8-17) 
3' GGACCUriIAC 5' (nts 76-85)
GLI1 stem II 5' CGG 3' (nts 22-24) 
3' GCC 5 '(nts 29-31)
GLI1 stem III 5' AGCU 3' (nts 42-45) 
3’ UCGA 5' (nts 53-56)
GLI1 stem IV 5' CAUC 3' (nts 59-62) 
3' GUAG 5’ (nts 70-73)
Table S2. List of the single stranded bases.
RNA Name and Region Unpaired Nucleotide Position
C-myc 5' GUU 3* (nts 14-16)
C-myc 5' AAACA 3' (nts 20-24)
C-myc 5' AAAA3' (nts 28-31)
C-myc 5' CCCC 3' (nts 35-38)
C-myc 5' AAAAAA 3’ (nts 54-59)
C-myc 5' ACAG 3' (nts 63-66)
C-myc 5' ACA 3’ (nts 70-72)
C-myc 5’ UG 3' (nts 76-77)
C-myc Stem Loop 5' UAGUUAU 3' (nts 43-49)
MITF 5’ UCU 3’ (nts 18-20)
MITF 5’ UUUUAU 3’ (nts 26-32)
MITF 5’ UU 3’ (nts 48-49)
MITF 5' A 3’ (nt 52)
MITF 5’ UUU 3’ (nts 56-58)
MITF 5’ GC 3’ (nts 62-63)
MITF *2 positions 5’ G 3’ (nt 10, 66)
XX
MITF Stem Loop 5' GGAAA 3' (nts 38-42)
Kras 5' CAACAAUA 3' (nts 9-16)
Kras 5' UCCUA 3' (nts 23-27)
Kras *2 positions 5' A 3' (nt 33, 37)
Kras *2 positions 5' C 3' (nt 58,62)
Kras 5' GAU 3' (nts 68-70)
Kras 5' GACACAGCA 3’ (nts 77-85)
Kras Stem Loop 5' AGUAAUUGAUGGAGAA 3’ (nts 40-55)
CD44 5' CCCAAUU 3 '(nts 11-17)
CD44 5' A 3' (nt 21)
CD44 5' C 3' (nts 39)
CD44 5' CCAGUU 3' (nts 43-48)
CD44 5' AC 3' (nts 52-53)
CD44 *2 positions 5' U 3' (nt 63, 88)
CD44 Stem Loop 5' CAAGAAU 3' (nts 27-33)
CD44 Stem Loop 5' CUCG 3' (nts 71-74)
CD44 Stem Loop 5' UGUGCU 3’ (nts 82-77)
MDR-1 5' GGGUG 3' (nts 6-10)
MDR-1 5' UUACAUU 3' (nts 22-28)
MDR-1 *2 positions 5' U 3' (nts 34,44)
MDR-1 5’ UGGAAGACAAAUACACAA 3' (nts 55-72)
MDR-1 5’ AAAA 3’ (nts 79-82)
MDR-1 Stem Loop 5' CAUUUU 3' (nts 38-40)
GLI1 5’ CC 3 '(nts 14-15)
GLI1 5' CAGA 3' (nts 18-21)
GLI1 5’ CACCUCACCC 3' (nts 32-41)
GLI1 5' UU 3' (nts 57-58)
GLI1 5’ CA 3' (nts 74-75)
GLI1 5' UC 3' (nts 78-79)
GLI1 Stem Loop 5' UUAU 3' (nts 25-28)
GLI1 Stem Loop 5’ CCCUCGU 3' (nts 46-52)
GLI1 Stem Loop 5' AACUCGC 3' (nts 63-69)
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Calculation of dissociation constant (Kd):
The percentage of bound RNA was determined using the opti-quant software 
(Figure S3).
WT
CRD-BP: «. w O-
Bound
Unbound 
100%
Figure S3. Autoradiograph to calculate the dissociation constant (Kd). Each 
autoradiograph that was generated was then used to calculate the Kd for CRDBP. Total 
signal from each lane (red lines) was calculated by drawing quantification boxes (blue 
boxes) around the signal generated from the [32P] c-myc CRD 1705-1886 RNA substrate. 
Kd values were then calculated using the Hill equation.
The average of at least 3 experimental replicates with at least 2 biological 
replicates had the average and standard deviation calculated (Table S3). The average and 
standard deviation was then plotted on a graph and the Hill equation was used to 
calculate the dissociation constant (Kd) (Table S3, Figure S3 and S4).
Table S3. Summary table of the calculated average percent bound and standard 
deviation for WT-CRDBP with c-myc 1705-1886 (182 nts) RNA.______________
[Protein] 
(nm
Percentage bound for four Average Percentage Standard
DeviationexDenmental replicates Bound
49.7 39.7 50.2 53.8
91.6 93.1
‘At least two protein preparations.
xxii
*
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Figure S4. WT-CRDBP binding curves as generated by the Hill Equation. WT-
CRDBP was incubated with [32P] c-myc CRD 1705-1886 from Table S3.
bound & L T
T55l=T7(®iIi7
Hill Equation
Kd= Dissociation constant 
L  = CRD-BP concentration 
n = Hill coefficient
Figure S5. The Hill Equation for calculating dissociation constant (Kd).
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